convergence - The University of Chicago Medicine Comprehensive ...

convergence 

vision | expertise | technology | community

At the University of Chicago Cancer 

Research Center, our mission is 

to understand, cure and prevent each of 

the scores of diseases we collectively call 

cancer. We pursue this goal by promoting 

collaboration among a diverse and dedicated 

team of outstanding laboratory scientists, 

caregivers, clinical researchers and trainees. 

These partnerships help us develop solutions 

tailored to the complexity of individual 

cancers and the unique needs of each 

patient. Our faculty and staff are dedicated 

to mentoring and inspiring the investigators 

of tomorrow while providing superior care 

to the people of today. 

1-2 

3 

5 

9 

13 

16 

19 

25 

28 

Letters: 

From the Director 

From the President of the Foundation 

and the Director of the Foundation 

Introduction: 

Divergence and Convergence 

Vision and Convergence 

Convergence of Expertise 

Technology and Convergence 

Community and Convergence 

Benefactors 

Foundation Boards and Auxiliaries 

Financials

This annual report is retrospective and prospective. It both reviews our activities in the 

2004-2005 fiscal year and explains how these efforts will shape our future. For the 

past 20 months, our members, staff, and supporters have engaged in a collaborative 

effort to design and implement a new strategic plan. This plan will help us take advantage 

of today’s numerous opportunities in medical discovery, advance the integration of the 

University’s wealth of resources, and enable us to enhance cancer care and bring the benefits 

of breakthrough science to our patients. 

The driving dynamic of this plan is convergence. It describes how we will promote 

collaboration, share our resources, and focus our endeavors in the development of new and 

better ways to prevent, diagnose, and treat cancer. The construction of the new Center 

for Biomedical Discovery is an example of convergence at work. The new building will be 

an integrated and richly creative environment that will facilitate interaction among our 

members and their colleagues in the biological, physical, and social sciences. It will engender 

discovery at the intersections of diverse disciplines, perspectives, knowledge, and expertise. 

Consequently, we are enormously excited about the future and confident in our ability to 

relieve some of the burden of cancer on our patients, their families, and our communities. 

This is a time of great optimism and hope, and I am thankful for the many people who have 

made this bright future possible. 

A Message from the Director o f t h e U n i v e r s i t y o f C h i c a g o C a n c e r R e s e a r c h C e n t e r 

I am thankful to my many colleagues who have employed their talent, wisdom, and 

dedication to make spectacular advances in cancer research. Their success in securing 

competive research grants demonstrates their excellence, as our research funding base has 

increased to $104,658,018. I regret that the abundance of the successes of my colleagues has 

made it impossible to include all the highlights of this year’s research in this report. We have 

space for only a small sample of their extraordinary achievements. 

I am also thankful for the support of our friends in the community and especially the 

assistance of the University of Chicago Cancer Research Foundation and the participation 

of other donors and groups. These supporters are vital to our ongoing success. 

In addition, I am thankful to the University for its faith in our work and its renewed 

emphasis on cancer research and care. Energized by this support, we are eager to confront 

tomorrow’s challenges. 

As you read this report, please be sensitive to the importance of your contributions. 

We accomplish none of our achievements in isolation. They all demonstrate the power of 

convergence. 

Respectfully, 

Michelle M. Le Beau, PhD 

Professor of Medicine and Human Genetics 

Director, University of Chicago Cancer Research Center 

Director, Cancer Cytogenetics Laboratory 

convergence | | UCCRC Annual Report 2004-2005

Ruth Ann Gillis McGuinnis 

Mary Ellen Connellan 

The past year has been one of reevaluation, renewal, and reformation. The University 

of Chicago Cancer Research Foundation (UCCRF) has been busy preparing itself 

for the electrifying times that lie ahead. This is a climactic moment in the history of 

cancer research. New knowledge and technologies offer the promise of enormous progress. 

Therefore, it is time to intensify our efforts, seize the opportunities, and reach for new 

heights above and beyond anything accomplished in years past. We will remain the Cancer 

Research Center’s faithful, enthusiastic and effective partner. 

In her first year as Director of the University of Chicago Cancer Research Center, Dr. 

Michelle Le Beau has implemented a comprehensive strategy to encourage greater 

collaboration among researchers, attract new talent to the University of Chicago, and 

provide its members with new assets to support their vital work transforming cancer 

prevention, diagnosis and care. At the UCCRF, we are ready to participate actively in the 

implementation of this agenda for action. 

That is why we are especially pleased at the Foundation record fundraising in Fiscal Year 

2004-2005 when we contributed $1,900,011 to the UCCRC. This amount exceeds last 

year’s total by more than $135,000. We are all grateful to our dedicated members and other 

generous donors who have made this extraordinary success possible. 

A Message from the President and the Director 

The Cancer Research Center has put these contributions to good use. We see the impacts of 

the Foundation’s giving at work throughout the University. Our donations – large and small 

– have enabled the purchase of state-of-the-art equipment, enhanced laboratory facilities, 

funded recruitment of top faculty and fellowships for young scientists, and generated 

innovative research by many of our most distinguished researchers. These scientists rely on 

this essential support because it provides them with the freedom necessary to pursue their 

most visionary investigations and explore new frontiers in cancer research. 

At the same time, we recognize that we must redouble our efforts and maximize every 

opportunity to increase our contributions in support of the UCCRC’s ambitious campaign 

to strengthen its operations. Staffing and equipping laboratories in the Center for Biomedical 

Discovery now under construction, for example, is an important and immediate challenge. 

This annual report makes a strong case for increased participation, because it demonstrates 

the power of our participation and the worthiness of the programs we support. We hope it 

will also make you proud of your role in this success and inspire you to become even more 

involved in the Cancer Research Center’s brilliant future. 

We thank each and every one of you for your wisdom, your commitment and your 

generosity. 

Sincerely, 

Ruth Ann Gillis McGuinnis 

President, 

The University of Chicago 

Cancer Research Foundation 


Director, 


Cancer Research Foundation

Divergence and Convergence 

Cancer is not a disease. 

It is scores of divergent diseases sharing a common origin: mutations in genes that enable aberrant cell growth. 

Normal genes trigger the processes that signal superfluous or damaged cells to self-destruct and make way for new 

healthy ones. Abnormal genes disrupt this critical aspect of the natural lifecycle of cells creating cancerous cells. 

These aberrant cells do not die even when they can no longer perform vital functions as effectively as their healthy 

counterparts and, in some cases, they acquire functions that their normal versions do not have. Furthermore, they 

multiply rapidly, displacing normal cells and invading healthy tissue. Too often, the result is organ failure and 

death. 

Wrapped in Mystery 

Nothing about this transition is simple. It involves countless chromosomes, genes, proteins, cells, and 

processes and innumerable, cellular, genetic, and chemical interactions performed at the molecular level. 

It is a process characterized by divergence and wrapped in mystery. 

Successfully unraveling the mystery of this complex, divergent group of diseases and helping cancer 

patients survive their disease requires a diversity of expertise, technologies, and perspectives. Researching 

abnormal cell growth demands the integration of resources, disciplines, and sciences and the collaboration 

of experts throughout the University and across the globe. The tradition of the individual researcher 

working long, isolated hours at the laboratory bench is passing. The hours are still long, but they are no 

longer lonely. Seeking better cancer cures and enhancing patient care call for the participation of medical 

professionals, patients, and the community of donors. 

Cooperation and Collaboration 

The need for a diversity of perspectives and expertise is why the UCCRC’s pioneering researchers 

emphasize multidisciplinary approaches and value cooperation and collaboration. Our modus operandi 

is to focus on building bridges, literal and figurative, that connect laboratories to clinics, strengthen the 

bonds between the University and communities, and bring departments, institutes, organizations, and 

facilities together. 

Over the years, the UCCRC has welcomed biologists, surgeons, radiologists, oncologists, pathologists, 

biochemists, radiation oncologists, epidemiologists, statisticians, physicists, chemists, psychiatrists, 

sociologists and geneticists intent on bringing new expertise and knowledge to enhance our understanding 

of cancer prevention, diagnosis, and treatment. Today, we are expanding our reach to encompass an even 

broader range of knowledge, information, and skills and ensure better care and quality of life for cancer 

patients. 


Convergence and Our Mission 

Convergence is fundamental to our mission, and it is evident in practically everything we do. It energizes 

our vision of the future and pervades our new strategic plan, which describes new programs and policies 

designed to promote convergence. The physical designs of our facilities – in place or under construction 

– also will advance this objective. Most of all, convergence helps us enhance cancer care and perform 

research that will serve future generations. 

Vision, Expertise, Technology, and Community 

The annual report for 2004-2005 focuses on this emphasis and how it shapes our planning, advances 

our research, and fuels breakthrough discovery. It explores how we encourage interaction for the benefit 

of cancer patients around the world and how convergence informs our vision, integrates our expertise, 

influences our use of technology, and strengthens our relationship with the community.

Vision and Convergence 

vision | expertise | technology | community 

Collaborative inquiry is the hallmark of the University of Chicago Cancer Research Center. Dr. John E. 

Ultmann, the driving force behind the creation of the UCCRC and its first Director, was an outspoken 

proponent of multi-disciplinary treatment of Hodgkin’s disease and other lymphomas, which are cancers 

of the lymphatic system. His innovative approach to treatment was instrumental in dramatically reducing the high 

mortality rates in this group of cancers. Death rates for Hodgkin’s disease, for example, have dropped by 60 percent 

since the 1970s. Cancer treatment at the University of Chicago continues to emphasize this multidisciplinary 

approach. Teams of medical oncologists, radiation therapists, surgical oncologists, geneticists, pathologists, and 

others meet to consider every patient’s case and recommend individualized treatment plans. 

Dr. Ultmann also understood that effective cancer research is cross-disciplinary, bringing together investigators 

representing a diversity of perspectives and expertise. The UCCRC became the fulfillment of his dream of an 

organization that would unite some of the world’s finest researchers in order to focus their efforts on basic, clinical 

and translational cancer research. “Translational research” transforms laboratory findings into the next generation 

of cancer therapies and potential cures. Today the UCCRC is comprised of approximately 190 clinical and basic 

scientists working together to discover new insights into cancer’s causes, characteristics, and cures. It has earned a 

global reputation for excellence, innovation and a commitment for attacking cancer from every angle. 

Evolution and Evaluation 

The UCCRC has sustained this level of success by continually examining and strengthening its programs. 

It has also periodically intensified this process of evolution and evaluation to address new challenges and 

take advantage of fresh opportunities. Currently, the Center is engaged in the most extensive process of 

reinvigoration and reinvention in its history. This year, the UCCRC developed a strategic plan to guide 

and help advance the University’s ambitious attempt to integrate the University’s cancer research efforts, 

maximize its resources, and employ them more effectively. 

One of the goals of this plan is to expand the breadth of the UCCRC and enhance its resources in cancer 

prevention and control. This will advance our objective to gain National Cancer Institute designation as a 

Comprehensive Cancer Center, which will more accurately reflect the depth and breadth of our research 

program. 

Tactics for Change 

The Strategic Plan outlines tactics designed to: 

• Strengthen our scientific programs; 

• Enhance the translational component of each program; 

• Promote multidisciplinary and interdisciplinary research; 

• Develop multidisciplinary, disease-specific working groups; 

• Increase the participation of basic scientists from all disciplines; 

• Upgrade existing shared facilities and create new ones where necessary; 

• Provide researchers with enhanced information technology resources; and 

• Expand our programs in cancer prevention and control. 


The plan will enable us to sharpen our focus on three “Discovery Hot Spots”: Metastasis, Cancer Prevention 

and Control, and Drug Discovery. These “Hot Spots” have enormous potential for reducing cancer death, 

mitigating its consequences, and lowering incidence for all types of cancer. Special working groups are 

evaluating existing efforts and developing plans to enhance our programs in these areas. 

Three “Hot Spots” 

Carrie Rinker- Schaeffer, PhD, and Charles Brendler, MD, head the Metastasis Working Group. Metastasis is 

the migration of tumor cells from one part of the body to another where they lodge and ultimately grow into 

a detectable tumor. It is the leading cause of cancer death. Most research, however, centers on the treatment of 

primary cancers and fails to consider metastasis as a distinct entity with its own dynamics. That is the mission 

of the new Ludwig Center for Metastasis Research which will enlist basic and clinical researchers in a uniquely 

targeted effort. Geoffrey Greene, PhD, Virginia and D.K. Ludwig Professor, and Ralph R. Weichselbaum, 

MD, Daniel K. Ludwig Professor, and Chairman, Department of Radiation and Cellular Oncology, who 

have expertise in both basic and clinical research, will serve as interim co-directors of the Center. We plan to 

recruit an internationally recognized scientist to be the Center director and two or three other scientists who 

will integrate new and existing expertise on metastasis to create a hub of research excellence focused on this 

critical issue. 

David Meltzer, MD, PhD, and Christopher K. Daugherty, MD, are developing the Cancer and Social 

Sciences Working Group to help address the second “Hot Spot,” cancer prevention and control. This type of 

research incorporates a wide range of possible investigations from the genetic, environmental, and behavioral 

determinants of cancer susceptibility to chemoprevention and early detection. Research demonstrates that we 

could prevent more than half of all cancer cases through the successful application of existing knowledge to 

modify behavioral risk factors for cancer. Effective research in this promising area requires the cooperative 

participation of clinicians, biologists, chemists, geneticists, and behavioral and social scientists. 

The drug discovery “Hot Spot” will build upon one of our greatest strengths, strategies for the identification, 

development, and evaluation of effective therapies that stem from our growing knowledge of the minute 

world of individual cells, genes, chromosomes and proteins. Multidisciplinary teams of clinical investigators 

representing Medical Oncology, Radiation Oncology, Pathology and appropriate surgical specialties analyze, 

test and develop experimental therapeutics and procedures. These groundbreaking efforts allow us to provide 

our patients with advanced treatments that are often available nowhere else. M. Eileen Dolan, PhD, and Dr. 

Geoffrey Greene lead the enhanced drug discovery program outlined in the strategic plan. 

Three Working Groups 

The UCCRC has also established three disease-specific working groups, which are studying women’s cancers; 

lung, head and neck cancers, and gastrointestinal cancers. We believe that grouping individuals around specific 

disease sites will facilitate and encourage translational research, and produce extraordinary results. Co-Leaders, 

with expertise in basic, clinical and population-based research, are responsible for these working groups. 

Many of the researchers working on these issues will ultimately be located in the Center for Biomedical 

Discovery (CBD). This extraordinary asset will facilitate the achievement of our vision. On October 17, 2005, 

the University broke ground on this $162.5 million research building, which will be the tallest structure 

on campus. The 333,760-square-foot building will house more than 700 investigators, technologists and 

administrative personnel engaged in or supporting state-of-the-art translational research. The building will 

have space for research teams in the Institute for Molecular Pediatric Sciences. These researchers will try to 

learn why diseases affect some children and not others, and why treatments work on some and fail on others.

Center for Biomedical Discovery 

New Laboratories 

Several floors of the building will be devoted to cancer research, including the home of the Ludwig Center 

for Metastasis Research. The UCCRC will have eleven dedicated laboratories for our investigators—many 

of them new recruits—who will engage in addressing the research priorities outlined in the Strategic 

Plan. Common areas and bridges will physically connect our researchers to their colleagues working in 

the biological, physical, and social sciences. The building will be adjacent and connected to the Center 

for Integrative Science, which is the home of the Ben May Institute for Cancer Research. Scientists 

representing the breadth of scientific inquiry will locate their labs and offices in the new building. 

Placing our researchers in close proximity to their colleagues working in the biological, physical, and 

social sciences, the CBD’s richly creative environment will be an incubator for realizing the potential of 

the exciting approaches outlined in our strategic plan. 

The CBD will be another manifestation of the philosophy of convergence that informs our history, 

harkens back to our beginnings, and drives the implementation of our Strategic Plan. This new facility 

will not only be a hub of productive, multi-disciplinary research but will also serve as a monument to the 

collaborative research that is at the heart of our mission. 

Seeking Cancer Cures On All Fronts | | UCCRC Annual Report 2003-2004 

7

Convergence of Expertise 


Sir Isaac Newton’s famous quotation – “If I have seen further it is by standing on the shoulders of Giants” 

– reminds us that scientists rarely make great discoveries in isolation. The vast majority of research 

breakthroughs are the products of hard work and the convergence of numerous insights by many creative 

investigators. Today, the explosion of information and the availability of increasingly sophisticated equipment 

and technology necessitate even greater interaction among scientists. The UCCRC has made significant advances 

in cancer research, because our scientists have welcomed the fertile sharing of ideas with their colleagues at the 

University of Chicago and with others across the globe. 

Consider the discovery of the drug Gleevec, which some believe to be the most promising cancer therapy of our 

time. Although the Food and Drug Administration (FDA) approved the drug for sale in May 2001, the process of 

discovery began more than 40 years ago when Dr. Peter Nowell reported that patients with chronic myelogenous 

leukemia (CML) consistently had a specific chromosomal alteration. The full implications of this discovery did not 

become clear until 1973 when Janet D. Rowley, MD, the University of Chicago Blum-Riese Distinguished Service 

Professor of Medicine, demonstrated that pieces of chromosome 9 and chromosome 22 had exchanged places. This 

translocation produces a cancer-causing protein called BCR-ABL. Dr. Rowley’s discovery prompted 27 years of 

additional research in America and Switzerland that ultimately produced Gleevec, which treats CML by inhibiting 

BCR-ABL. Thus, one of the greatest cancer advances of our time required dozens of investigators and four decades 

of research before it could become readily available to help cancer patients. 

Discovery as a Cooperative Effort 

Discovery is a cooperative effort, and many of the UCCRC’s significant advances involve multiple 

investigators and technologists. Our labs are not places for individual inquiry, but small communities 

where investigators and technologists share common missions. Often these communities come together 

to address promising avenues of research. 

For example, a broad, interactive, and multidisciplinary group of investigators with strong records in 

research in cancer genetics, cell growth and survival, experimental drug development, and state-of-theart 

blood-related cancer research, collaborate to discover treatments for leukemias and lymphomas that 

remain major challenges. This group includes, among others, Michael J. Thirman, MD; John Anastasi, 

MD; Wendy Stock, MD; John Crispino, PhD; Michelle M. Le Beau; PhD, Stephen J. Kron, MD, PhD; 

Richard A. Larson, MD; Koen van Besien, MD; and Amittha Wickrema, PhD. 

Expanding and Crossing Boundaries 

Often such collaboration crosses the boundaries separating traditional disciplines. Dr. Geoffrey Greene, 

and Milan Mrksich, PhD, Professor of Chemistry, work closely together in research at the interfaces of 

chemistry, biology and materials science. Their research, for example, focuses on the identification of small 

molecules that inhibit proteins essential to the growth and/or survival of malignant breast cancer cells. 


The Convergence of Disciplines 

Cancer’s growing complexity also encourages the convergence of existing disciplines to create new ones. 

Pharmacogenomics is the integration of genetics, pharmacology, and medicine to analyze how a person’s 

genetic makeup influences his or her body’s response to drugs. This information is invaluable in enhancing 

the effectiveness and safety of cancer drugs. M. Eileen Dolan, PhD and Mark J. Ratain, MD, the Leon O. 

Jacobson Professor of Medicine, and their colleagues have worked together to make the UCCRC a world leader 

in this promising new field. 

Dr. Dolan used pharmacogenomics to develop an innovative approach to study effectiveness and toxicity 

of a class of cancer drugs called platinating agents. (Platinating agents alter the DNA of abnormal cells in 

order to block their proliferation.) One drawback to genetic studies assessing the impact of cancer drugs 

is that researchers obviously cannot give an anticancer drug to test its impacts on healthy family members 

who do not have cancer. Therefore, they cannot directly assess the heritable variables that determine how 

the drug will affect individuals. Dr. Dolan has developed a comprehensive, unbiased model to elucidate how 

genetic differences alter the effects of anticancer agents. She used cell lines collected from 692 members of 55 

multi-generational families to identify genetic traits related to pharmacodynamic effects. This comprehensive 

approach makes it possible to identify the impact of any gene without having to make a priori assumptions 

about specific classes of genes. 

Dr. Mark Ratain and Federico Innocenti, MD, PhD, use genetic analysis to identify patients at high risk for 

life-threatening toxicity from irinotecan, one of the few drugs effective for cancers of the colon and rectum. 

This work led directly to the insertion in the drug’s product label of a “Warning” to inform physicians that 

genetic testing may call for a reduction in dosage and consequent toxicity. In addition, the University is in the 

process of identifying one or more companies that may be able to commercialize the test so that physicians can 

use this discovery to guide treatment choices and protect patients. Dr. Carrie Rinker-Schaeffer, a nationally 

recognized leader in metastasis research, and her laboratory identified a unique gene that specifically inhibits 

prostate cancer growth. She and her colleagues are currently investigating how this MKK4 protein induces 

tumor dormancy of cancer cells. 

Convergence and Cancer Clinical Trials 

Dr. Ratain has also collaborated with Walter M. Stadler, MD, in a clinical trial to study the efficacy and safety 

of an experimental drug, sorafenib. They demonstrated the drug’s usefulness in treating kidney cancer. These 

significant findings led to an international Phase III clinical trial and the recent filing of a New Drug Application 

by the sponsors (Onyx Pharmaceuticals and Bayer Pharmaceuticals) to market the drug for metastatic kidney 

cancer. It is expected that the FDA will approve sorafenib for treatment of patients with this disease. 

This trial was one of the many performed at the University. In 2004, the UCCRC enrolled 1,170 patients in 

160 cancer clinical trials, more than any other research facility in Illinois. These clinical trials enable cancer 

patients to obtain promising cancer drugs before the FDA makes them available for general use. 

In another trial, Dr. Wendy Stock and Olatoyosi Odenike, MD, demonstrated the potential of the experimental 

drug depsipeptide, which alters the structure of our DNA, for treating patients suffering from acute myeloid 

leukemia. Dr. Gini Fleming is investigating how to improve antihormone therapies for young women with 

endocrine-responsive breast cancer. These women have a high risk for recurrence if not treated with antihormone 

therapies. 

Hedy Kindler, MD, Director of Gastrointestinal Oncology has investigated the effectiveness of combining the 

cancer drug gemcitabine with the novel targeted agent bevacizumab to treat pancreatic cancer, one of the most 

deadly malignancies. The success of this effort has lead to a national clinical trial of this regimen, also chaired 

by Dr. Kindler, which could lead to FDA approval of this combination. 

Dr. Koen Van Besien and the Leukemia-Lymphoma Transplantation Program are engaged in a clinical trial 

of umbilical cord blood stem cell transplantation. The goal of this study is to increase access to bone marrow 

transplantation treatment for patients without a compatible donor.

Mitchell C. Posner, MD, Chief of the Section of General Surgery 

and Surgical Oncology, is collaborating with Irving Waxman, MD, 

in clinical trials studying two novel endoscopic ultrasound guided 

injection therapies for treatment of advanced pancreatic and esophageal 

cancer. (An endoscope is an optical system for observing the inside of a 

hollow organ or other body cavity.) 

Thomas Gajewski, MD, PhD, and his team are engaged in clinical trials 

examining the efficacy of vaccines for melanoma and other cancers. 

Dr. Gajewski leads the Immunology and Cancer Program, which 

focuses on the mechanisms of immune responses and immunotherapybased 

cancer trials. The program includes Dr. Albert Bendelac and his 

investigators who study the role of natural killer T cells (NKT). At a 

relatively young age, Dr. Bendelac made a discovery that caused a stir 

among immunologists around the world. He characterized a type of T 

cell, called a natural killer T cell, which is unusual for its targeting of 

lipids instead of proteins. (Lipids are fats and a key component of cell 

membranes.) In March 2005, The Howard Hughes Medical Institute 

(HHMI) selected Drs. Bendelac and Milan Mrksich as new HHMI 

investigators. Only 43 investigators nationwide earned this prestigious 

honor in 2005. 

Evaluating Existing Therapies 

The UCCRC examines ways to make existing therapies most effective for patients. Suzanne Conzen, 

MD, discovered that hormones called glucocorticoids can initiate signaling mechanisms in breast cancer 

cells that block their death and inhibit chemotherapy effectiveness. This is of concern because a synthetic 

glucocorticoid, dexamethasone, is often administered to patients immediately prior to chemotherapy to 

diminish chemotherapy side effects. Studies are ongoing to determine whether dexamethasone might, 

therefore, result in the unwanted effect of reducing tumor response to chemotherapy. In a similar effort, 

Drs. Wendy Stock and Stephen Kron are developing a test that will allow physicians to predict how Gleevec 

will affect individual patients both in terms of toxicity and effectiveness. 

Marcus Peter, PhD, is pursuing a provocative hypothesis suggesting that some types of chemotherapy may 

actually promote the spread of cancer. Dr. Peter suspects that these therapies might reprogram “killer” 

enzymes into ones that help tumor cells survive. 

The Ben May Institute for Cancer Research 

Dr. Peter is a member of the Ben May Institute for Cancer Research, which focuses on the basic research 

that is fundamental to clinical advancements. Some of the UCCRC’s most fruitful collaborations involve 

interactions between basic and clinical researchers. The scientists of the Institute are also members of the 

UCCRC, and they have made fundamental discoveries that have helped clinical researchers enhance cancer 

prevention, diagnosis and treatment. This year, the members from the Institute have expanded the boundaries 

of knowledge of cellular dynamics and increased our knowledge of the processes that lead to cancer. 

For example, Piers Nash, PhD, investigates how proteins work in combination to produce sophisticated 

signals at the single cell level. Schooled in biochemistry, cell biology and bioinformatics, Dr. Nash and 

his lab integrate these disciplines to probe the molecular mechanics of signal transduction that are so 

intricately involved in malignancy. Dr. Nash is also utilizing computational tools to understand cellular 

communication networks and is developing a massive, integrated database called Proteoscape, which will 

make information on millions of proteins available to researchers worldwide. 

convergence | | UCCRC Annual Report 2004-2005 

11 

Marsha Rosner, PhD, the Director of the Ben May Institute for Cancer Research and the Charles B. Huggins 

Professor, also studies the intricate signaling processes that initiate cell growth. She has identified key molecules 

that suppress or activate angiogenesis, which tumors use to develop blood vessels and obtain vital nutrients.

Her discovery will help scientists develop therapies that suppress angiogenesis and starve tumors. Dr. Rosner 

has also found another molecule that is overactive in patients with head and neck cancer. Suppression of this 

target can block the growth and proliferation of malignant cells. 

Kay Macleod, PhD, studies the role of oxidative stress in cancer. Oxidative stress is the cellular damage caused 

by free radicals, which are highly reactive chemicals that can promote the development of atherosclerosis, some 

cancers, and other conditions. Antioxidants protect cells against these harmful effects, which is why they are 

such a vital part of a healthy diet. 

Sharing Expertise 

These are just a few examples of how UCCRC members put their expertise to work producing invaluable 

breakthroughs in our understanding of cancer and benefiting patients. Sharing this expertise is one of our 

chief functions, and we have introduced numerous procedures for ensuring interaction between basic and 

clinical researchers. For example, the UCCRC sponsors a monthly lecture series on translational inquiry. At 

each meeting, a basic researcher and a clinical researcher present on a particular topic. These presentations and 

the discussions that follow help bridge the gap between basic and clinical research. 

This focus is also evident in the teaching of cancer biology. The Committee on Cancer Biology offers an 

interdisciplinary program of studies leading to either a PhD degree in Cancer Biology or postdoctoral training 

in preparation for research and teaching in this field. The program’s introductory graduate level course is 

unique to the University of Chicago. It provides budding cancer biology researchers with a working knowledge 

of the pathophysiology and treatment of human cancer so that the students can consider their basic research 

projects in the context of current problems faced in detecting, preventing and treating human cancer. 

Consequently, the course is taught by a team of instructors that includes a surgical pathologist, a basic scientist 

who uses animal models to recapitulate human disease, and a physician-scientist. This year’s students are being 

introduced to the intricacies of cancer biology by Amy Noffsinger, MD, who is an expert in cancer pathology; 

Akira Imamoto, DDS, PhD, who uses genetically modified mice to study the mechanisms that control cell 

growth; and Suzanne Conzen, MD, a medical oncologist whose laboratory studies molecular pathways in 

breast cells that allow them to survive under conditions that would normally induce cell death. In contrast to 

the traditional introductory PhD course in cancer biology, this unusual approach aims to give basic scientists 

a foundation for their future experimental work by outlining the biological challenges faced by both the 

clinicians who diagnose and treat cancer and the patients who experience cancer’s harmful effects. 

Of course, the sharing of expertise goes far beyond the walls of 

the University and the Hospitals. Thoracic oncology provides 

an example of the many partnerships linking the UCCRC 

with other institutions. Dr. Ravi Salgia is leading an ambitious 

research program in lung cancer in collaboration with the 

Roswell Park Cancer Institute (RPCI) in Buffalo, New York. 

RPCI’s strengths, especially in the area of chemoprevention 

and smoking cessation programs complement the UCCRC’s 

best features. The University takes a strong leadership in clinical 

cooperative groups that integrate national cancer clinical trial 

efforts. It is the host institution for the Cancer and Leukemia 

Group B (CALGB) clinical cooperative group chaired by Dr. 

Richard Schilsky. The University is also an active member 

of the Children’s Oncology Group (COG), Gynecologic 

Oncology Group (GOG), and Radiation Therapy Oncology 

Group (RTOG). 

The members of the UCCRC represent a wealth of knowledge and expertise, which they bring enthusiastically 

to the study of cancer. One cannot help but believe that Sir Isaac Newton would have embraced this culture of 

collaboration and welcomed our disciplined and diligent investigators as colleagues.

Technology and Convergence 


There is considerable evidence that cancers begin as single cells. These cells double at least 30 times before the 

tumors are big enough to be detected clinically. By then, each tumor weighs approximately one gram and 

contains one billion cells. (A gram equals .03 ounces.) Even at this miniscule size, the tumors may already 

have evolved enough to metastasize and become deadly. 

Therefore, clinicians strive to diagnose and treat tumors as early in their development as possible or, even better, 

prevent their genesis altogether. Some of the deadliest cancers (e.g. lung, liver, esophageal, ovarian, and pancreatic) 

have low survival rates, in part, because they present few early symptoms and diagnosis often comes too late to 

do any good. If we treat these tumors before they become established, the more effective we are likely to be in 

extending patient survival and improving quality of life. 

At the Molecular Level 

Consequently, some researchers are peering at cancer genesis at the most fundamental levels, and others 

are developing advanced imaging techniques that help community clinicians to detect cancer earlier and 

more effectively. Many of our researchers focus on the individual proteins and genes that regulate the life 

cycle of each cell. Some of these microscopic substances regulate the signaling processes that tell cells to 

proliferate, self-destruct, and perform other functions. 

By combining their expertise with the latest in technology that allows them to work at the most 

fundamental levels of biology, UCCRC scientists are able to analyze subtle changes in cells and organs, 

look for molecular markers that suggest propensities to cancer, and diagnose malignancies earlier in their 

development. 

Investigating Molecular Structures 

Dr. Greene’s lab, for example, uses X-ray crystallography to study 3D molecular structures in order 

to understand more completely communication mechanisms that tell nuclear receptors, such as the 

estrogen receptor, how to respond to hormones and SERMs (selective estrogen receptor modulators). His 

observations have broad implications both for predicting receptor behavior and for the design of drugs 

useful in the treatment and prevention of breast cancer. Sophisticated technology available at the Argonne 

National Laboratory (ANL) facilitates Dr. Greene’s exploration of this miniature world. 

The ANL has been an integral component of the University of Chicago since the Manhattan project 

began in 1942. The Laboratory recently developed a Structural Biology Center built around the Advanced 

Photon Source. Large enough to enclose a baseball park, this technology is capable of generating the most 

brilliant X-ray beams in the nation. This technology allows Dr. Greene to gain insights critical to our 

understanding of how hormones bind to their receptors to transmit signals and how we can modulate this 

process to develop improved therapies. 


13

Advances in Imaging and Computer Aided Diagnosis 

Technology also helps UCCRC researchers and clinicians detect cancers in patients well before overt 

symptoms appear and tumor growth becomes widespread. They use artificial intelligence to develop 

Computer Aided Diagnosis (CAD) strategies that offer radiologists a technological “second opinion” when 

analyzing images from mammography screenings, ultrasound, computed tomography (CT), and magnetic 

resonance imaging (MRI). This work effectively and efficiently improves the interpretation of images, greatly 

reducing the incidence of missed cancers. 

Samuel G. Armato III, PhD, and Heber MacMahon, MD, are 

developing automated methods for comparing multiple chest 

radiographs of the same patient. By accurately integrating a 

series of chest radiographs over time, the techniques they are 

perfecting enable radiologists to more easily and effectively 

identify subtle, but critically significant, changes. 

Breast cancer radiological screening is not always perfect, and, 

at times, may result in false negatives and false positives. It can 

be very difficult to determine if a spot on an image is a cancerous 

lesion or something totally benign. This is particularly true of 

younger women who typically have denser breasts. To meet this 

challenge, Greg S. Karczmar, PhD, and Gillian Newstead, MB, 

ChB, FACR, are exploring high spectral and spatial resolution 

MRI. They are proving that this enhanced form of MRI is very 

useful in early detection and staging of breast cancer. 

Robert M. Nishikawa, PhD, and Maryellen Giger, PhD, are 

evaluating breast tomosynthesis, which is a promising new 

technology that produces two-dimensional slices through the 

breast to create a three-dimensional image. In conventional, twodimensional 

mammography, overlapping breast tissues can either 

obscure or mimic cancers. One of the drawbacks of this technique 

is that the radiologist has more images to read. Drs. Nishikawa 

and Giger are developing computer-aided detection methods to 

assist radiologists read the large volume of image data. 

State-of-the-Art Surgery 

Patients and physicians like Diane Yamada, 

MD, benefit from advanced imaging 

technologies. Dr. Yamada specializes in the 

diagnosis and treatment of gynecologic 

cancers. She is the principal investigator at 

the University of Chicago for the Gynecologic 

Oncology Group (GOG), a cooperative clinical 

trials group supported by the National Cancer 

Institute. 

Advanced technology is also playing a vital role in the operating room. Surgeons Gregory Zagaja, MD, and 

Arieh Shalhav, MD, are refining robotic surgery techniques that provide much better outcomes for patients 

than more conventional approaches. In the past three years, Drs. Zagaja and Shalhav have performed almost 

400 robotic-assisted radical prostatectomies (excisions of part or all of the prostate gland) using the robotic 

da Vinci surgical system, which provides improved visualization and decreased blood loss. 

Since the two doctors have found that robotic surgery provides earlier and better recovery of both urinary 

control and sexual function, the vast majority of prostate cancer surgeries done at the University of Chicago 

are now performed using this approach. 

Drs. Shalhav and Zagaja are bringing the benefits of sophisticated, state-of-the-art equipment directly to 

patients. Like many of the researchers and clinicians at the University of Chicago, they are pushing new 

technology to its limits and demonstrating the importance of expertise. Employing advanced technology 

to full effectiveness begins with experienced, skilled scientists with the ability and creativity to take it to the 

next level.

Michael Vannier, MD, a founder of the field of computational 

anatomy and a leader in the development of three-dimensional 

imaging, uses a 64-slice computed tomography scanner to 

develop three-dimensional “movies” of a patient’s internal organs 

without having to resort to invasive procedures. These images 

study one patient’s kidneys from a variety of perspectives. 


15

Community and Convergence 


The lab and the clinic are not the only domains for breakthrough cancer research. The research at the UCCRC 

does not end at the boundaries of the University. This is where it often begins. 

The UCCRC reaches far into local communities to engage the support and participation of the public, provide 

programs that help people understand, avoid and deal with cancer, as well as gain information that helps us 

investigate the underlying community dynamics that influence the distribution of malignancy. These efforts enable 

us to advance a critical element of our mission: cancer control and prevention. 

The Power of Prevention 

The nation could cut cancer deaths in half if all Americans became determined to live healthier lives and 

participate in screening programs using existing technologies. According to the American Cancer Society, 

tobacco use will cause 168,140 cancer deaths nationwide this year, and another 190,090 deaths will be the 

consequence of physical inactivity, poor nutrition, excess body weight, and other lifestyle choices. 

Charles B. Brendler, MD, and his team investigated the relationship between dietary fat and prostate 

cancer in Jamaican men who have the highest known incidence of prostate cancer in the world. They 

have expanded this study to include Swedish men who also have a high incidence, and Japanese men who 

have a very low incidence. This study holds the promise of providing helpful guidance encouraging men 

to adjust their diets to prevent this malignancy, which will afflict 232,000 additional American men in 

2005. 

Dr. Andrea King’s laboratory is addressing the smoking problem head on. Her studies have demonstrated 

a relationship between drinking alcohol and cigarette cravings. Furthermore, she has demonstrated that 

these cravings intensify proportionately with increased levels of alcohol intake. In addition, Dr. King has 

been involved in community-based smoking cessation programs, and she is examining the usefulness of a 

medication (naltrexone) in helping people quit smoking. 

Kyle Hogarth, MD, and his colleagues also offer smoking cessation programs to the community. They 

focus on helping individuals at high risk for lung cancer, mesothelioma, and other malignancies. 

Helping High-Risk Individuals 

Serving people at risk is the goal of another program, the Cancer Risk Clinic. Olufunmilayo Olopade, 

MBBS, directs the Clinic, which offers comprehensive risk assessment to people in the community. The 

Clinic considers, in particular, the genetic risks associated with, breast, ovarian, colon, pancreatic, and 

endometrial cancers. It also looks at other types of cancer and strives to treat patients from a comprehensive 

perspective encompassing the specific needs of each patient or family member. Dr. Olopade’s creative 

and visionary approaches to cancer prevention and treatment have gained worldwide recognition. The 

MacArthur Foundation recently named her a MacArthur Fellow. This prestitigous award is known 

informally as the “genius grant.”

Dr. Olopade is a member of the team of researchers, led by Sarah Gehlert, PhD, from diverse disciplines 

that earned one of eight highly competitive grants to create a Center for Interdisciplinary Health Disparities 

Research (CIHDR). The remain team members include Martha McClintock, PhD, Suzanne Conzen, 

MD, Thomas Krausz, MD, FRCPath, Christopher Masi, MD, PhD, and Dr. Olopade are pursuing health 

disparities research that analyzes differences in cancer incidence and development across various social and 

ethnic groups. Based at the University’s Institute for Mind and Biology (Dr. McClintock, Director), the center 

integrates the diverse expertise of social workers, psychologists, physicians and molecular geneticists to explore 

the psychosocial and genetic causes of breast cancer in African-American women, including neighborhoods, 

social isolation, stressors and medical co-morbidities. 

The new Center is just one of the many initiatives designed to bring diverse disciplines together and increase 

our impact on local communities. It complements the developing UCCRC “Cancer and the Social Sciences 

Program,” mentioned in the “Vision and Convergence” section in this annual report. This effort will provide 

cross-disciplinary research in technology assessment, genetics, risk assessment and intervention, health 

outcomes, health disparities, quality of life, and medical ethics. 

Information and Counseling for Patients and their Families 

We also reach out to communities by providing valuable information and counseling. For example, the UCCRC 

created the University of Chicago Cancer Resource Center to meet the cancer information needs of patients, 

their friends and families, and the general public. Several years ago the American Cancer Society (ACS) joined 

this effort, and the Center became part of the Society’s Patient Navigation Services, a nationwide effort 

designed to ease the burden of cancer on patients and their families. This collaboration helps people learn 

about cancer in all of its many manifestations, cope with its uncertainties, learn about ongoing cancer clinical 

trials, get answers to their most troubling questions, and link with other worthwhile community resources. 

Divya Jain of the UCCRC and Liz Ferrigno of the ACS manage the Center.

Education for the Community 

Our numerous efforts to provide community physicians with the latest clinical information offer another 

illustration of our close links with the community. A case in point is the effort of the Thoracic Oncology 

Program, led by Ravi Salgia, MD, PhD, to educate doctors throughout the Chicago region on the latest 

advances in cancer prevention, diagnosis and treatment. Teams of program members are presenting 

the same lecture series at various locations throughout the region. Each meeting in the series focuses 

on a particular malignancy. Dr. Salgia’s team discusses lung cancer, Dr. Kindler’s group presents on 

mesothelioma, and head and neck cancer is the topic of the team led by Dr. Everett Vokes, MD, the John 

E. Ultmann Professor of Medicine and Radiation and Cellular Oncology. 

Chicago Mayor, Richard 

M. Daley, Maggie Daley, 

seven-time Tour de 

France Champion Lance 

Armstrong, and Cancer 

Research Center Director 

Michelle M. Le Beau, PhD, 

at a rally to promote the 

value of cancer clinical 

trials. 

Educating the community about the importance of cancer clinical trials was the goal of our sponsorship 

of a health fair and rally to welcome to Chicago cancer survivor and seven-time Tour de France Champion 

Lance Armstrong and the Bristol-Myers Squibb Tour of Hope. The event, produced in collaboration 

with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, attracted thousands 

of people to the Chicago Loop. UCCRC Director Michelle M. Le Beau and other dignitaries, including 

Armstrong and Chicago Mayor Richard Daley, spoke to the crowd about how clinical trials translate 

discoveries made in the lab into promising new treatments and procedures that enhance patient care. 

The UCCRC serves numerous groups of people and communities. It also derives invaluable support from 

the people in surrounding neighborhoods and the entire region. Invariably, we depend on communities 

of people from the patients who participate in life-saving clinical trials to the community leaders who 

recognize the importance of our contribution to the region. One of the most important groups is the 

community of volunteers and contributors who help make our work possible. This critical community 

provides us with guidance, a voice in the region, and valuable funds that we leverage to attract financial 

support from government agencies and cancer organizations. (More detailed information on this 

community is available later in this report.) 

Ultimately, the essence of the UCCRC is collaboration. At the heart of our organization is an abiding 

faith in creative and fruitful interaction with individuals, colleagues, communities, patients, disciplines, 

cancer organizations, government agencies, and other cancer centers and institutions of higher learning.

The University of Chicago Cancer Research Center 

Thanks those who contributed from July 1, 2004 to June 30, 2005 to cancer and cancer-related programs 

at the University of Chicago. 

Director’s 

Leadership Circle 

$1,000,000 + 

Rabbi Morris I. Esformes 

Diamond Circle 

$250,000 - $1,000,000 

American Cancer Society 

The Breast Cancer Research Foundation 

Cancer Research Institute 

Cancer Research Foundation 

Thomas J. Duckworth and 

Connie Duckworth 

Kadrovach-Duckworth Family Foundation 

Susan G. Komen Breast Cancer Foundation 

Leukemia & Lymphoma Society 

UCCRF Women’s Board 

Sapphire Circle 

$100,000-$249,999 

American Society of Clinical Oncology 

Amererican Society for Therapeutic 

Radiation Oncology Ed 

Ben May Charitable Trust 

Cancer & Leukemia Group B Foundation 

The Entertainment Industry Foundation 

Mr. and Mrs. Vincent Foglia 

Genentech, Inc. 

Sidney Kimmel Foundation 

Joy McCann Foundation, Inc. 

Mrs. Mary Jane O’Connor 

William F. O’Connor Foundation 

The Ovarian Cancer Research Fund, Inc. 

Richardson, Patrick, Westbrook 

& Brickman, L.L.C. 

Mr. and Mrs. Gordon I. Segal 

UCCRF Associates Board 

The V Foundation 

Ruby Circle 

$50,000 - $99,999 

American Association for Cancer Research, Inc. 

AstraZeneca LP 

Blum-Kovler Foundation, Inc. 

Mrs. Joy Daugherty 

Frank Consolidated Enterprises, Inc. 

Mr. and Mrs. James S. Frank 

Charles Hammersmith & 

Carol Hammersmith Family Foundation 

Leukemia Research Foundation, Inc. 

Mr. Earl Meltzer 

Pfizer U.S. Pharmaceuticals Group 

Mr. Nicholas Kenneth Pontikes 

Mr. George Rusu 

UCCRF Auxiliary Board 

Windy City Classic Foundation 

Platinum Circle 

$25,000 - $49,999 

Amgen Inc. 

Berlex Laboratories, Inc. 

The Wendy Will Case Cancer Fund, Inc. 

Harry F. & Elaine Chaddick Foundation Inc. 

Children’s Cancer Research Fund 

Citigroup Business Services 

Mr. and Mrs. Marvin L. Conney 

Mr. and Mrs. Jeffrey Diermeier 

Enivar Charitable Fund 

Mrs. Leonard S. Florsheim, Jr. 

Goldman, Sachs & Company 

Peter G. Horton Charitable Remainder 

Annuity Trust 

Klein Tools Charitable Foundation 

The Lisa Klitzky Foundation 

Ms. Eva B. Levi 

Richard & Martha Melman Foundation 

Alan M. Miller Foundation for Kidney 

OfficeMax Inc. 

Richemont North America, Inc. 

Mr. Anthony Santacroce 

Valda & Robert Svendsen Foundation 

Gold Circle 

$10,000 - $24,999 

John W. Anderson Foundation 

Banc of America, LLC 

C N A Foundation 

Mrs. Kathleen E. Chapski 

Mr. and Mrs. Benjamin D. Chereskin 

Chicago White Sox Charities, Inc. 

CIBC World Market Corp. 

Jordan L. Daniels, M.D. 

Mr. L. M. de Kool 

Brian Delanty Invitational 

Driehaus Capital Management, Inc. 

Mr. and Mrs. Richard L. Duchossois 

Mr. Bruce William Duncan 

Exelon Corporation 

Fidelity Investments 

Fidelity Charititable Gift Fund 

Mr. and Mrs. Richard Gonzalez 

The Albert Goodstein Family Foundation 

Graff Diamonds (U.S.A.) Inc. 

Grant High School Friends of UCCRF 

Gulf Lumber Co. 

Mr. and Mrs. Charles Harrold III 

Illinois-Eastern Iowa Dist. of Kiwanis 

Junior Cancer League 

Charles S. Lazerwitz Charitable Trust 

Mrs. Judy A. Lewis 

David C. MacGregor, M.D. 

Ms. Noreen McGuire 

Mr. and Mrs. Bernard D. Meltzer 

Ms. Rita Meltzer 

Mercer Human Resource Consulting 

J. P. Morgan Chase 

Motorola, Inc. 

Ortho Biotech Inc. 

Mr. and Mrs. Bruce D. Ovitz 

Pfizer Inc. 

Prentiss Properties Acquisition Partners, L.P. 

Michael Reese Health Trust 

Riviera Country Club & Sports Center 

Sara Lee Corporation 

United Way of Metropolitan Chicago 

Mr. James M. Weichselbaum 

Mr. and Mrs. Richard M. Woldenberg 

Mrs. Jane Woldenberg 

Silver Circle 

$5,000 - $9,999 

Mr. Barry S. Alberts 

Allstate Insurance Company 

Ayco Charitable Foundation 

Baxter International Inc. 

Mr. and Mrs. Lawrence Benjamin 

Mrs. Tybe Blink 

Bristol-Myers Squibb Company 

Estate of Lillian Z. Bronkhurst 

Mr. and Mrs. Harris C. Brumfield 

Mrs. Pauline M. Burelli 

Mr. and Mrs. Richard C. Carr 

Mr. Kevin J. Cogan 

Credit Suisse First Boston LLC 

Ms. Rebecca Davidson and 

Mr. Richard Geddes 

Mr. and Mrs. Ronald Duitsman 

Peter and Virginia Foreman Foundation 

The Gillette Company 

GlaxoSmithKline 

Mr. Michael C. Harris 

Mr. Robert A. Helman 

K-Five Construction Corporation 

Mrs. Michael Klein 

Ms. Carol Koterski Dugan 

Mr. William J. Krug 

Otto W. Lehmann Foundation 

Mr. Laurence Lewis 

Marlowe Corporation 

Marsh USA Inc. 

Mr. Marvin Miller 

Modestus Bauer Foundation 

Moneris Solutions Inc. 

Neal, Murdock & Leroy, LLC 

Mr. Stephen D. Nechtow 

The Northern Trust Company 

Organization Fund of the University 

of Illinois at Urbana-Champaign 

Ms. René C. Pasche 

Mr. and Mrs. Robert K. Robinson 

Mitchell Ross Childrens Cancer Fund 

RST Memorial Cancer Foundation 

Mr. and Mrs. Paul Rubschlager 

Mrs. Ethelyn Schreiber 

Schreiber Foundation for Cancer Research 

Mr. and Mrs. Gerard Schulte 

University of Illinois at Urbana-Champaign 


19

Bronze Circle 

$2,500 - $4,999 

A & D Miller Foundation 

Mr. and Mrs. William Adams IV 

Alberto-Culver Company 

Alternative Reproductive 

Resources 

Mr. and Mrs. J. Douglas Bacon 

Bear Necessities Pediatric Cancer Fd. 

Mr. and Mrs. Frank S. Brumfield 

Mr. Donald J. Buchert 

Mrs. Gregory Chun 

Mr. and Mrs. Thomas L. Cox 

Mr. and Mrs. Michael Crane 

Mr. and Mrs. Andrew Da Miano 

Mr. and Mrs. Thomas C. D’Aprile 

Duk Young Foundation 

Mr. and Mrs. Thomas Hardin 

Mr. and Mrs. Steven Helms 

Mr. Austin L. Hirsch and 

Ms. Beth Gomberg-Hirsch 

Mr. and Mrs. William Krug 

Mr. Seymour Kulick 

Mr. and Mrs. Andrew R. McGaan 

Mr. and Mrs. Micharl McGuinnis 

Mr. J. Clifford Moos 

Mr. and Mrs. Robert Mueller 

North Central Sect. Amer. 

Urol. Assoc. 

Mr. and Mrs. David Nuelle 

Oppenheimer & Co. 

Mr. Alan Oremus 

Ms. Mary Bliss Packer 

The Pittsburgh Foundation/ 

Patricia L. Knebel Memorial 

Fund 

Mr. and Mrs. Thomas Reusché 

Ridgeview Industries 

Ms. Susan M. Riley 

Mr. and Mrs. Frank C. Schell III 

The Ralph & Lois Silver 

Foundation 

Mr. Scott L. Stimpson 

Mr. G. S. Stimpson 

Mr. and Mrs. John Svoboda 

Mrs. Lorraine Vandenbergh 

Vanguard Charitable Endowment 

Mr. and Mrs. Robert Von Halle 

Ms. Joyce A. Wambold 

Ms. Rosalind Wattel 

Winston & Strawn LLP 

Mr. and Mrs. James R. 

Woldenberg 

Founders 

$1,000 - $2,499 

All Seasons Home 

Improvements, Inc. 

Aileen S. Andrew Foundation 

Applied Medical 

Mr. and Mrs. John Atchison 

Bank of America, Illinois 

Mr. and Mrs. James N. Bay, Jr. 

Bays Corporation 

Mr. and Mrs. Thomas Begel 

William Blair & Company 

Mr. and Mrs. Darcy R. Bonner 

Mr. and Mrs. Don Borzak 

Ms. Janna Bounds 

Mr. and Mrs. James Brady 

Mr. Stephen Brenner 

John & Jacolyn Bucksbaum 

Charitable Fund 

Ms. Mary Burnstine and 

Mr. Gerald Skoning 

Mr. and Mrs. Michael J. Busch 

Mr. and Mrs. William F. Cahill 

Mr. Alvin Chereskin 

Click Commerce, Inc. 

Mr. and Mrs. Robert Conrad 

ContiGroup Companies 

Foundation 

Mrs. Theresa A. Costello 

Mr. and Mrs. Theodore K. Davis 

Mr. and Mrs. David W. 

Devonshire 

Mr. and Mrs. John J. Dombek, Jr. 

Mr. and Mrs. Richard F. Duffy 

Mr. and Mrs. Wayne I. Elliott 

Ms. Deborah M. Engel 

Mrs. Fred Feinstein 

Dr. and Mrs. Frank Fitch 

Mr. and Mrs. Timothy Flood 

Focus Surgery 

Mr. and Mrs. David W. Fox, Jr. 

Ms. Wende Fox and 

Mr. James Lawson 

Fox Lawson Management 

Consulting Inc. 

Mr. and Mrs. Louis E. 

Freidheim, Jr. 

Gastro Intestinal Research 

Foundation 

Mr. Ronald Goldman 

Sheldon F. Good Family 

Charitable Fdn. 

Gorter Family Foundation 

Dorothy & Freeman F. Gosden, 

Jr. Foundation 

Mr. Richard Gray 

GRG Investment Partnership, LP 

Mr. and Mrs. Raj Gupta 

Hagopian Family Foundation 

Mr. and Mrs. Brian Hahn 

Mr. and Mrs. Thomas Hall 

Mr. and Mrs. Robert Hartman 

Mr. William H. Hartz, Jr. 

Mr. and Mrs. William Hokin 

Mr. Edward Hortick 

International Foodservice 

Manufacturers Association 

Mr. Robert M. Janowiak 

Mrs. Peggy O. Jones 

Mr. David N. Jones 

Ms. Mary E. Karnosky 

Mr. and Mrs. Thomas Kennedy 

Mr. and Mrs. Thomas Eric 

Kilcollin 

Mr. and Mrs. Donald A. King, Jr. 

Kirby Sheet Metal Works, Inc. 

Mr. John F. Kofler 

Leonard & Ruth Kriser 

Foundation 

Mr. and Mrs. Gilbert W. 

Kurschner, Jr. 

L.E.K. Consulting LLC 

Ms. Brian Latronico 

Lavin Family Foundation 

Mr. Alan A. Lazzara 

Dr. Michelle M. Le Beau and 

Dr. Robert Harwood 

Mr. Roger J. Leyden 

Lilly 

Mr. John W. Luther 

Ms. Elizabeth J. Martin 

Marziani Enterprises, LLC 

Mr. and Mrs. Roger McEniry 

Mr. and Mrs. Patrick McGarvey 

Dr. and Mrs. McKay McKinnon 

Ms. Marsha Meskan 

Mr. and Mrs. Edward J. Miller 

Mrs. Karol J. Moller 

Mudd Family Foundation 

Mrs. Evelyn H. Nathanson 

Mr. R. Gregory Neidballa / 

Saddle & Cycle 

Niamogue Foundation 

Mr. Daniel E. O’Neil III 

Orange Crush, LLC 

Mr. and Mrs. Kirby Pearson 

Mr. and Mrs. Robert Peterson 

Astellas Pharma 

Mr. and Mrs. Heber Pierce 

Mr. Gerald Pilot 

Mr. and Mrs. Gordon Lee Pollock 

Mr. Thomas S. Postek 

Mr. Roger H. Reckers 

Mr. and Mrs. Paul J. Reilly 

Mr. Evan B. Richards 

Ms. Pamela M. Rojc 

Mr. and Mrs. William Rose 

Mr. James L. Rosenbloom 

RTG - Prairie LLC 

Mr. Scott Sauer 

Mr. and Mrs. James H. Schink 

Schumacher Capital LLC 

Mr. and Mrs. Richard Scully 

Mr. Lee S. Selander 

Servall Company 

Mr. and Mrs. Rex Sessions 

Mr. Daniel M. Shepherd 

Ms. Jean E. Sheridan 

Mr. Sherwin Siegel 

Mr. and Mrs. Robert W. Siegfried 

Julie and Brian Simmons 

Foundation 

Mr. Lawrence Skatoff 

Mr. John Stanfill 

Stuart-Rodgers Ltd. 

Ms. Cynthia J. Swartzloff 

Dr. Richard Thometz 

Mr. Samme Thompson 

Oakleigh L. Thorne Fund 

Mr. and Mrs. Barton G. Tretheway 

Mr. and Mrs. Timothy H. Ubben 

Mr. and Mrs. Gary Verhoeven 

Ms. Nancy E. Voss 

Dr. David Derwoei Wang 

Mr. and Mrs. Keith Ward 

Mr. and Mrs. William Wardrop 

Mr. and Mrs. David C. Wenger 

Mr. and Mrs. Michael Werner 

Mr. and Mrs. J. Reading 

Wilson, Jr. 

Mr. and Mrs. Steven W. Wolf 

Mr. Walter S. Wormser 

Benefactors 

Under $1,000 

Mr. and Mrs. Gustavo O. Abello 

Mr. and Mrs. John Ackerman 

Ms. Barbara Stolberg Adelman 

Mrs. Arthur M. Adler, Jr. 

Ms. Joan G. Adler 

Agape Foundation 

Mr. and Mrs. Ronald J. Allen 

Mr. and Mrs. William Allind 

Mrs. Cheryl Allind 

Allstadt Hardin Foundation 

Mr. and Mrs. Richard Almeida 

Almeida Family Foundation 

Dr. and Mrs. Stephen Alport 

Altair Advisers, LLC 

Ms. Marilyn K. Alter 

The Ambriance! Trust 

Ms. Marilyn Amento 

American Urological 

Association Inc. 

Mr. and Mrs. Keith B. Andersen 

Mr. and Mrs. Jack Anderson 

Ms. Betty-Alice Anderson 

Mrs. Catherine R. Anderson 

Mr. and Mrs. Craig Andrews 

Mr. and Mrs. Everett W. Andrus 

Ms. Jacqueline Annes 

Mr. and Mrs. Larry Antonatos 

Ms. Jean M. Antoniou 

Aon Foundation 

Ms. Helena B. Appleton 

Mr. and Mrs. Frank E. Arnold 

Ms. Kathy Arnold 

Ms. Marcia Aronow & Family 

Atlas Metal Industries, Inc. 

Ms. Rita Atwood 

Ms. Diane Patricia Atwood 

Mr. Erwin K. Aulis and 

Ms. Sharon V. Kristjanson 

Aurora Foundation 

Mr. Randy Aussenberg 

Ms. Marta Holsman Babson

Mr. and Mrs. Nick Babson 

Mr. Robert P. Baids 

Ms. Suzanne M. Baker 

Ms. Kim Baldo 

Bank One Corporation 

Bank of American United Way 

Campaign 

Mr. and Mrs. Chris Barber 

Mr. and Mrs. James L. Barna 

Mr. Alan M. Bartelstein 

Ms. Maureen Connors Barton 

Ms. Carol M. Bartucci 

Ms. Margaret C. Bass 

Mr. and Mrs. Roger Baum 

Ms. Svea Herbst-Bayliss 

Mrs. Salli Behrstock 

Mr. and Mrs. William Belman 

Mr. and Mrs. Thomas Belskis 

Ms. M. Elizabeth Bennett 

Mr. Eugene Bensinger and 

Ms. Lynn Straus 

Ms. Bonnie J. Benson 

*Mrs. R. Ford Bentley 

Mr. Peter J. H. Bentley 

Ms. Robin Berg 

Ms. Margaret Berger and 

Mr. Michael Friedman 

Berger, Newmark & Fenchel, P.C. 

Dr. Earl O. Bergersen 

Ms. Catherine Berkemeyer 

Mr. and Mrs. Arthur Berman 

Ms. Danielle Berns 

Mr. Charles E. Bidwell 

Mr. and Mrs. Richard C. Billett 

Ms. Carol L. Billett 

Ms. Mary Streckert Binder 

Ms. Rosanna Bisulca 

Mr. and Mrs. Randell S. 

Blackburn 

Marcia E. Blake, O.D. 

Ms. Priscilla L. Blattner 

Mr. and Mrs. Dan Blau 

Mrs. Leah Block 

Mrs. Harvey Block 

Raymond S. Blunt & Company 

Ms. Lisa J. Bock 

Dr. and Mrs. Joseph Boggs 

Mr. and Mrs. David Bomier 

Mr. Thomas A. Bond 

Mr. and Mrs. Scott Bondurant 

Mr. Abraham Bookstein 

Ms. Cheri L. Bornheim 

Mr. and Mrs. Raymond H. 

Bosworth 

Ms. Mary T. Boyle 

Ms. Sarah Josephine Boyle 

Mr. Bruce C. Boynick 

Ms. Colleen Kenney Bracco 

Mr. and Mrs. Brian J. Brady 

Mr. Brooke Brady 

Ms. Donna Brady 

Mr. James F. Brady, Jr. 

Mr. Lawrence J. Brannian 

Mr. Willard E. Bransky 

Ms. Florence Stapler Braudy 

Ms. June H. Braun-Leibowits 

Ms. Melva J. Breitenstein 

Ms. Arlene Brennan 

Mrs. Sheila M. Brennan-Johnson 

Mr. and Mrs. Neil Brilliant 

Mr. and Mrs. Daniel N. Brock 

Mr. and Mrs. Brian J. Brodeur 

Ms. Tracy Q. Brooker 

Brookeridge Aero Associates, Inc. 

Mr. Joseph W. Brosnan 

Ms. Myra J. Brown 

Mr. and Mrs. Murray Brown 

Ms. Laura K. Brown 

Mr. and Mrs. Allen Brown 

Mrs. Merle P. Brown 

Richard & Patricia Bruder 

Foundation 

Mr. and Mrs. Hardy Brumfield 

Mr. John H. Bryan 

Ms. Sheri A. Bucciferro 

Mr. and Mrs DeWitt Buchanan 

Mr. and Mrs. John A. Buck 

Mr. Stuart D. Buck 

Mr. and Mrs. Ronald Budil 

Mr. and Mrs. Allan E. Bulley III 

Mr. and Mrs. Irwin Buntman 

Ms. Kim T. Burke 

Mr. and Mrs. John Burnstine 

Mr. William F. Cahill 

Ms. Marie P. Calusinski 

Campia Family Foundation 

Ms. Kathleen A. Capone 

Ms. Ellen Capua 

Ms. Anne M. Carey 

Mr. and Mrs. Douglas R. Carlson 

Mr. and Mrs. Martin S. Carlson 

Mrs. Diane B. Carlson 

Ms. Theresa M. Carmody 

Ms. Kathy L. Carney 

Mr. Sean Michael Carney 

Ms. Joanne Foltz Casey 

Mr. Frank D. Cella 

Ms. Shelby L. Chaden 

Ms. Maria D. Chakos 

Ms. Susanne K. Chakos and 

Ms. Vickie D. Lukas 

Mr. Steven M. Champlin 

Mr. and Mrs. Alger B. Chapman 

Mr. Philip J. Charleson 

Mr. and Mrs. James Cherney 

ChevronTexaco 

Chicago Model Productions 

Chicago Dowel Co., Inc. 

Chicago Sun-Times 

Childhood Leukemia Foundation 

Mr. and Mrs. Edward E. 

Christensen 

Mr. and Mrs. Don Chudacoff 

Ms. Gerri Cicchinelli 

Mr. and Mrs. Charles F. Clarke III 

Mr. and Mrs. Henrik Clausen 

Ms. Laurie A. Cohen 

Mr. William S. Cohen 

Mrs. Inez Cohen 

Mr. and Mrs. Tasso H. Coin 

Ms. Elaine Stone Colburn 

Mr. and Mrs. Neil Coleman 

Ms. Julie A. Collins 

Committee to Elect James A. 

DeLeo 

Ms. Dorothy Conger 

Mr. and Mrs. Kevin A. Connellan 

Ms. Shirley E. Connors 

Mr. Francis M. Connors 

Law Office of Matthew J. Conti 

Mr. and Mrs. Fred Cook 

Mr. William H. Cooley, Jr. 

Ms. Deborah Corbeil 

Mrs. Deborah Sharko Corcoran 

Mr. and Mrs. J. Patrick 

Corsiglia, Jr. 

Corus Bank, N.A. 

Ms. Clea Costa 

Mr. and Mrs. David Cox 

Mr. and Mrs. Jeffrey Coyner 

Ms. Mary T. Cozzens 

Mr. and Mrs. John F. Cregan 

Mr. James N. Criss 

Mr. and Mrs. J. Michael Crouch 

Arie and Ida Crown Memorial 

Fund 

Ms. Johanna Steinmetz 

Cummings 

The Honorable Barbara Currie 

and Mr. David P. Currie 

Mr. Thomas J. Curtin 

Mr. and Mrs. Richard W. Cusack 

Mr. and Mrs. Charles F. Custer 

Mr. and Mrs. Walter J. Dabransky 

Ms. Diane Dahl 

Ms. Judith M. Daly 

Mr. and Mrs. Thomas Dammeyer 

Mr. and Mrs. Ryan M. D’Aprile 

Ms. Lindsay M. D’Aprile 

Mr. John B. David 

Mrs. Robert M. David 

Mr. and Mrs. Thomas Davis 

Mrs. Lori Davis 

Ms. Pamela S. Day 

Ms. Susanna Decker 

Ms. Deborah L. DeHaas 

Mr. John A. Delaney 

Delavan Community Chest 

Senator James A. DeLeo 

Deloitte Consulting LP 

Delta Dental Plans Association 

Mr. Norman E. Demb 

Mr. and Mrs. Charles Demirjian 

Ms. Jane M. Demler 

Mr. and Mrs. John Derse 

Mr. Herman J. Desmidt 

Ms. Kathryn E. DeVaris 

Mr. and Mrs. Raymond A. 

Devorkin 

Mr. and Mrs. W. Brinkley 

Dickerson, Jr. 

Mr. John N. Dietzen 

Ms. Wanda C. Dill 

Mr. Mark S. Disbrow 

Mr. and Mrs. Nicholas A. 

Dispensa 

Diversified Food Sales System Inc. 

Ms. Alice Feeney Doherty 

M. Eileen Dolan, Ph.D. 

Mr. Jay L. Dolgin 

Mr. and Mrs. Richard S. 

Donoghue, Jr. 

Erin W. Donoghue 

Mr. and Mrs. David Donovan 

Ms. Colleen M. Donovan 

Mr. and Mrs. Robert D. Douglass 

Ms. Charenton Zelov Drake 

Ms. Margaret A. Cremins 

Mr. and Mrs. Keith Drollinger 

Mr. and Mrs. Michael Dry 

Mrs. Helene Dubow 

Mr. George E. Duchossois 

Ms. Mary Stephanie Duffin 

Ms. Barbara Gaucher Duffy 

Ms. Christine Dullum 

Mr. and Mrs. John Dyer 

The Ebersbach Family 

Ms. Bernice C. Eckelkamp 

Ms. Lynn Eikenbary 

Ms. Maggie Smith Ekman 

Mr. and Mrs. Ross D. Emmerman 

Mr. and Mrs. John W. Empfield 

Mr. and Mrs. John G. Encher 

Ms. Carole Engberg 

Ms. Alix Engel 

Mr. Bill T. England 

Ms. Judith J. Erfurth 

Mrs. Kathy Even 

Mr. and Mrs. Michael Even 

Dr. Brian David Fagel 

Ms. Maureen E. Fahey 

Ms. Christine M. Fallon & Family 

Dr. Ahmed A. E. Fareed 

Ms. Kari Farkvam 

Ms. Mary Ellen Faust 

Mr. Jeffrey Feeney 

Fellers Fixtures, Inc. 

Mr. Carl Fellers 

Mr. and Mrs. Gary Fencik 

Ms. Diana S. Ferguson 

Ferolito, Vultaggio & Sons 

Dr. and Mrs. Anthony G. Finder 

Fine Arts Engraving Company 

Fine Designs LLC 

Mr. and Mrs. Robert Finkel 

Dr. Philip Fireman 

Mr. and Mrs. H. Barney Firestone 

First Data Western Union 

Foundation 

Ms. Margaret A. Fischer 

Ms. Lois M. Fisher 

Mr. and Mrs. Richard S. Fleisher 

Ms. Kellianne Fleming 

Mrs. Mary B. Flynn 

Ms. Mary Therese Foley 

Ms. Anne M. Forde 

Dr. Harry A. Fozzard 

Mr. and Mrs. Arthur E. Frame, Jr. 

Ms. Georgia Frances 

Ms. Olivia F. Frank 

Ms. Susan Frank 

Ms. Cynthia Frank 

Mr. and Mrs. Philip Franklin 

Ms. Christine C. Franklin 

Ms. Debra Frederick 

Ms. Lynn Fredrick 

Mr. and Mrs. John E. Freund 

Mr. and Mrs. Edward Freundlich 

Mr. Charles H. Fries, Jr. 

Mrs. Cindy R. Friman 

Mr. and Mrs. Sidney Frisch 

Mr. Henry J. Frisch 


21

Ms. Elise W. Frost 

Mr. Ernest Fruehauf 

Funkhouser Vegosen Liebman & 

Dunn, Ltd. 

Ms. Stella R. Furmanek 

Barbara Vaughan Gabor, Ph.D. 

Mr. and Mrs. Michael P. Galvin 

Ms. Katie Gancer 

Mr. Rocio Garcia 

Mr. and Mrs. Donald F. Gardner 

Ms. Sharon Garell 

Mr. and Mrs. Vladimir Gastevich 

Ms. Lili Gaubin 

Ms. Karen M. Gaudio 

Mr. and Mrs. James B. Gaw 

Mrs. Martha F. Gearhart 

Mr. and Mrs. Gary Gehlhoff 

Mr. James I. Gelbort 

Ms. Hope F. Geldes 

Ms. Corinna L. Gelster 

Geno’s Decorating, Inc. 

Mr. Pasquale Genova 

Ms. Andrea O. Gerow 

Ms. Nancy A. Gerstadt 

Ms. Sally D. Gibbs 

Mrs. Kay F. Gillespie 

Mr. Andrew S. Gold 

Mr. and Mrs. Dennis K. 

Goldman & Family 

Ms. Bernadette Goldman 

Goldman Sachs Philanthropy 

Fund 

Mr. and Mrs. Rodney L. 

Goldstein 

Mr. Leonard S. Goldstein 

Mr. and Mrs. David Gomez, Jr. 

Ms. Leah M. Gonzalez 

Mr. and Mrs. James S. Gordon 

Ms. Patricia M. Gorman 

Gortho Ltd. 

Ms. Karen L. Granda and Mr. 

John Mrowiec 

Mr. Herve Granjean 

Ms. Carrie S. Grant 

Ms. Patricia Grauf 

Drs. Geoffrey and Marianne 

Greene 

Mrs. Ronald Greenspon 

Mr. and Mrs. Larry Greenstein 

Mr. Robert M. Green 

Mr. and Mrs. David D. Gregg 

Mr. Geoffrey F. Grossman 

Mr. Jeffrey Charles Groulx 

Mr. and Mrs. David Grumhaus, Jr. 

Mr. Francis B. Gummere, Jr. 

Mrs. Donna Gumminger 

Mr. and Mrs. Laurence 

Guthmann 

Mr. and Mrs. Rodger A. Haga 

Ms. Bernice L. Hajduk 

Ms. Sheila Hammond 

Ms. Suzanne Hammond and 

Mr. Richard Leftwich 

Ms. Rita Hanna 

Ms. Jennifer L. Hansen 

Ms. Georgia D. Harbin 

Mr. and Mrs. John Hardin 

Mr. and Mrs. Sheldon T. Harris 

Mr. and Mrs. Kenneth A. 

Harris, Jr. 

Ms. Clarice A. Harris 

Mr. David Hartsell and Ms. 

Wendie Reece 

Mr. Charles L. Haskell 

Healing Heartaches 

Mr. and Mrs. O. J. Heestand, Jr. 

Ms. Svea Herbst-Bayliss 

Hereau, Inc. 

Mr. and Mrs. Bruce Heyman 

Ms. Leslie Hickey 

Hickey Foundation Inc. 

Mr. Leo F. Hickman 

J. Patrick Hieber, M.D. 

Mr. Edgar L. Hiestand, Jr. 

Mr. and Mrs. Larry Hill 

Mr. James J. Hipp 

Mrs. Ellen Hirsch 

Mr. and Mrs. George Hirsh 

Mr. Richard Henry Kleeman 

Mr. and Mrs. Henry Hodge 

Mr. and Mrs. Mark R. Hoffman 

Mr. Robert T. Hofmann 

Mr. Thomas Hoglund 

Ms. Harriet T. Holderness 

Mr. and Mrs. Willard Hollinger 

Mr. Michael P. Hood 

Mr. H.B. Hubachek, Jr. 

Paul and Pandy Huff 

Ms. Mardi B. Huffman 

Mr. Richard E. Hulet 

Mr. and Mrs. William P. Hummer 

Ms. Patricia Cox Hunckler 

Ms. Sharon Hunter 

Hilarie and Justine Huscher 

Mr. Leland E. Hutchinson and 

Ms. Jean E. Perkins 

Mrs. Barbara K. Hyman 

Mr. Ralph Iacono 

Mr. and Mrs. Peter Ianello 

Ms. Donna Krier Ioppolo 

Mr. and Mrs. Timothy Irons 

Mr. and Mrs. Robert T. Isham, Jr. 

Ms. Ruth J. Jackson 

Mr. and Mrs. Daniel L. Jackson 

Mr. and Mrs. Roy C. Jackson 

Ms. Victoria Jackson 

Mr. William L. Jackson 

Mrs. Jacqueline J. Jackson 

Ms. Phyllis Jacobellis 

The Jaffee Foundation 

Mr. and Mrs. Keith Jans 

Mr. Eric L. Jensen 

Ms. Anne K. Jensen 

Jewish Federation of Metro 

Chicago 

Mr. and Mrs. Steven E. Johnson 

Mr. and Mrs. Joseph C. Johnson 

Mr. and Mrs. Wayne M. Johnson 

Ms. Sheila M. Brennan-Johnson 

Mr. Don Johnson 

Mr. and Mrs. Richard Johnston 

Mr. and Mrs. R. Stuart Johnstone 

Dr. and Mrs. Burrill N. Josephs 

Ms. Betty Z. Kahnweiler 

Mr. David A. Kallick 

Mrs. Gail Kamensky 

Mr. and Mrs. Thomas G. Kamp 

Mr. Jeffry W. Kamrow 

Ms. Jean Kane 

Mrs. Denis S. Karnosky 

Mr. and Mrs. Robert F. Keeling 

Ms. Carol W. Keenan 

Ms. Mary L. Kelly 

Ms. Kathryn Lynn Kemp 

Ms. Dorothy L. Kern 

Mrs. William T. Kernahan 

Ms. Beverly Keseric 

Mr. and Mrs. Roger W. Kieffer 

Mr. and Mrs. William Kies 

Ms. Linda Scherer Kimball 

Mrs. Janet Kimmel 

Mr. James King 

Kirkland & Ellis Foundation 

Drs. Diane and William Kleiber 

Mr. and Mrs. Wayne Klein 

Ms. Monica Davidson Klinke 

Mr. Lawrence A. Klong 

Mr. and Mrs. Ray Kluth 

Rachel Kohler and Mark 

Hoplamazian Charitable 

Fund 

Mr. and Mrs. Jerry Komas 

Mr. and Mrs. Bernard Kompare 

Mrs. Arthur Korach 

Ms. Andrea Kott 

Ms. Paula Kovarik 

Ms. Ann Kowalsky and 

Mr. Jerrold E. Salzman 

Mr. Richard Koz 

Mr. and Mrs. Harry M. 

Kraemer, Jr. 

Ms. Mary L. Krausfeldt 

Dr. and Mrs. Norton Kristy 

Mr. and Mrs. Donald F. Kroesch 

Ms. Anne Kruchko 

Ms. Gale J. Kryzak 

Mr. John A. Kuhlman, Jr. 

Mr. and Mrs. Greg Kunkel 

Pat and Gib Kurschner 

Mr. and Mrs. Phillip A. 

Kurschner 

Ms. Kelly Smith Kurschner 

Ms. Sue Pauparas Kurz 

The Lacina Family 

Ms. Gale Lacina 

Mr. and Mrs. Lucian LaGrange 

Ms. Cathy Z. Lalich 

Ms. Mary Patricia Landa 

Mr. and Mrs. Marc D. Landsberg 

Dr. Robert M. Lang 

Jones Lang LaSalle Americas Inc. 

Ms. Rachel Langtry 

Jennifer and Joey Lansing 

Ms. Lois A. Lapper 

Mr. Hugh V. Larkin 

Ms. Whitney Lasky 

Mr. Jerry Latherow & Kersten 

Stenson 

Mr. William R. Lauer 

Mr. and Mrs. Greg Lawton 

Mr. and Mrs. Tom Leahy 

Ms. June H. Braun-Leibowits 

Mr. and Mrs. Peter Leibowitz 

Mr. and Mrs. Frank A. Leone 

Levenfeld Pearlstein LLC 

Mr. Michael H. Levine 

Elaine & Donald Levinson 

Foundation 

Mrs. Janet Lewis 

Mr. and Mrs. David L. 

Liebman III 

Mr. David L. Liebman, Jr. 

Mr. and Mrs. James Limper 

Ms. Jacqueline Locola 

Mr. Edward S. Loeb 

Ms. Audrey W. Loeb 

Mr. and Mrs. Robert Logan 

Mrs. Robert Logan 

Mr. William Lopatin 

Mr. David S. Lott 

Ms. Sophia Lotus 

Mr. and Mrs. James Luebchow 

Mr. and Mrs. Mathew Lunn 

Mr. and Mrs. Michael Courtney 

Lynch 

Ms. Margaret A. Lyons 

Mr. and Mrs. Saul Mackler 

Dr. and Mrs. Amos Madanes 

Mrs. Carl J. Madda 

Ms. Felice M. Madda 

Mr. and Mrs. William R. Madden 

Ms. Christine Majkrzak 

Mr. Stephen A. Malato 

Mr. Barry Malkin and 

Ms. Jodi Block 

Mr. and Mrs. Barry J. Maloney 

Mr. and Mrs. Richard T. Manak 

Mr. Charles Manker 

Ms. Joan Daniels Manley 

Mr. and Mrs. Steve Manus 

Mr. Michael A. Marchese 

Marchese Educational Therapy 

Mr. Paul R. Marchi 

Mariani Enterprises, Inc. 

Mr. James R. Marino 

Mr. and Mrs. Raymond J. 

Markman 

Ms. Jill Marotta 

Ms. Valerie K. Martinson 

I. Martusciello 

Mr. and Mrs. Ronald A. Marwitz 

Dr. Alfred Marx 

Ms. Evelyn Matasar 

Mr. and Mrs. Kent Mathy 

Mr. and Mrs. Robert W. 

Matthews 

Mr. and Mrs. David May 

Ms. Florence B. Mayefsky 

Mrs. Frank D. Mayer 

Ms. Terese O. Mayer 

Ms. Linda Mays 

Ms. Maureen McAnney 

Mr. and Mrs. Paul McCarthy 

Dr. and Mrs. James B. 

McCormick 

Mr. Jerold K. McCoy 

Ms. Patsy McCurdy 

Mr. and Mrs. John McDermott

Mr. and Mrs. James McDonough 

Ms. Beryl McDonough 

Mr. Thomas J. McFadden 

Ms. Laura K. McGrath 

Ms. Isabella McIlveen 

Mr. and Mrs. James McNaughton 

Mr. and Mrs. Corey B. 

McPherrin 

Ms. Evelyn McSherry 

Mr. and Mrs. Elmer J. Mears 

Ms. Cassandra M. Mellor 

Ms. Rita Meltzer 

Mr. and Mrs. Harold Merrill 

Mr. and Mrs. Richard Merrill 

Merrill Lynch 

Ms. Gail E. Mesch 

Mr. Burton C. Meyer 

Mrs. Alan H. Mayer 

Mr. and Mrs. Dieter B. Meyer 

Mrs. Karen L. Meyer 

Mr. and Mrs. David J. Meyers 

Ms. Cari A. Meyers and 

Mr. Ralph Sacks 

Mary Elizabeth Meyers 

Mr. Dan Michael 

Mr. and Mrs. Robert Mignin 

Mr. and Mrs. Edward Mikusch 

Ms. Barbara Jo Miller 

Ms. Barbara A. Miller 

Mr. and Mrs. Milton Minkin 

Mr. Sanford Mintz 

Ms. Doreen W. Mitchell 

Ms. Laura Davis Molk 

Mr. and Mrs.Steven Molo 

Ms. Patricia A. Monahan 

Ms. Shauna M. Montgomery 

Mr. and Mrs. William H. 

Moore IV 

Mr. and Mrs. James Moore 

Mr. and Mrs. Joseph Moos 

Mr. Joseph J. Morgan 

Mr. Lawrence Morgan 

Morgante-Wilson Architects, Ltd. 

Mr. and Mrs. James Moriarity 

Mr. and Mrs. Robert S. Morrison 

Ms. Amy Fairbanks Morro 

Mr. and Mrs. William Morrow 

Mr. and Mrs. Richard A. Mortell 

Mr. and Mrs. David Mosher 

Mr. Sidney Moskowitz 

Mrs. Melva J. Breitenstein 

Dr. Douglas Mufuka 

Mr. and Mrs. Wylie H. Mullen 

Mr. Paul E. Mullen 

Mr. and Mrs. Bruce Mumford 

Mr. and Mrs. Robert S. Murley 

Murphy, Meldroy, Melvin 

Murphy 

Ms. Melody Murphy 

Ms. Michelle G. Nacker 

Mr. Paul R. Napleton 

Mr. Robert Napleton 

Mr. and Mrs. James Nappo 

National Philanthropic Trust 

DAF 

Navarro Negrete Properties, LLC 

Mr. and Mrs. Scott Needham 

Marlo Good Nelson and 

Joel Nelson 

Ms. Patricia B. Newell 

Mr. Jerome J. Niemann 

Ms. Katherine E. Nikolai 

Ms. Christina Nixon 

Mrs. Di-Anne Norbut 

Northern Trust Company 

Charitable Trust 

Mr. and Mrs. Lawrence Novak 

Ms. Laura E. Nowicki 

Ms. Rosemarie Nowicki 

Ms. Elizabeth I. Nowicki 

Nuveen Investments 

Ms. Kathleen M. O’Brien 

Mr. Jeffrey S. O’Dwyer 

Mr. and Mrs. Cole Oehler 

Mr. Victor B. Olason 

Katherine L. Olson Charitable 

Foundation 

Ms. Elaine Olson 

Oracle Corporation 

Mr. and Mrs. Stuart Oran 

Mr. and Mrs. James G. Orphan 

Ms. Janis Lynn Oshensky 

Ms. Cherilyn K. Ovca 

Mrs. Donald R. Owen 

Ms. Nana Owusu 

Dr. Diane and Mr. Thomas Ozog 

Ms. Jodiann Pacer 

Mr. and Mrs. Eugene T. Paddock 

Ms. Geraldine Page 

Ms. Kathleen Palla 

Mr. and Mrs. David Palmer 

Mrs. Lynne A.J. Palmore 

Mr. and Mrs. Carl J. Panek 

Ms. Kathleen Park 

Mr. and Mrs. G. Douglas 

Patterson, Jr. 

Mr. and Mrs. W. Andrew Patton 

Arvydas Paulikas 

Levenfeld Pearlstein 

Mr. and Mrs. Marshall Peck 

Ms. Georgy Ann Peluchiwski 

Ms. Eileen Pembroke 

Mr. and Mrs. Ian Pensinger 

Ms. Jean E. Perkins 

Mr. James Perlman 

Mr. and Mrs. Richard Peske 

Ms. Jane E. Petkus 

Petty & Bielik Orthodontics, P.C. 

Ms. Gail A. Petty 

Mr. William Phipps 

Ms. Minnie S. Phoenix 

Ms. Amanda Pierce 

Ms. Elaine Pietrini 

Ms. Carol A. Pilliod 

Ms. Lisa M. Pines 

Ms. Sue Pinsky 

Mr. and Mrs. Scott D. Pirkins 

Mr. and Mrs. John J. Piva, Jr. 

Ms. Mary A. Planek 

Ms. Wendy Planek 

PND Inc. 

Mrs. Mac Pohn 

Mrs. Rhonda Pohn 

Mr. Eliaz Poleg 

Mr. and Mrs. Michael L. 

Pontarelli 

Mr. and Mrs. Edward Pope 

Portfolio, Inc. 

Mr. and Mrs. R. Clifford Potter 

Praecis Pharmaceuticals 

PricewaterhouseCoopers LLP 

Frederick H. Prince Trust/Prince 

Charitable Trusts 

Progressive Slovene Women of 

America 

Mr. and Mrs. Peter Prokopowicz 

The Prudential Foundation 

Mr. Kenneth R. Pyburn 

Mrs. Diane L. Quackenbush 

Mrs. Joan M. Quillman 

Mr. Robert E. Rashkin 

Ms. Susan M. Redden 

The Research Team 

Mr. John T. Rettaliata 

Mr. and Mrs. J. Christopher 

Reyes 

Mrs. Anne Reyes 

Mr. and Mrs. Tom Reynolds 

Ms. Catherine C. Rhomberg 

Mr. Roger Rhomberg 

Ms. Catherine D. Rice 

Ms. Dolores M. Richert 

Ms. Suzanne S. Ridenour 

Mr. Paul R. Ridenour, Sr. 

Mr. Harold S. Ridenour 

Mr. and Mrs. Harold D. Rider, Jr. 

Ridgemoor Chapels, Inc. 

Ms. Connie Riemer 

Mr. Thomas F. Rochford 

Ms. DeAnne Rogers 

Ms. Dona C. Roper 

Mrs. Maryann Rosenberg 

Mr. Matthew Rosenshine 

Drs. Marsha Rosner and 

Robert Rosner 

Ms. Marcia Roubik 

Ms. Mary Roucka 

Mr. and Mrs. Eric Rowley 

Mr. and Mrs. Arlen D. Rubin 

Mr. Albert B. Rubin 

Ms. Adele Rubin 

Mr. and Mrs. Howard Rudolf 

Ms. Lori Runquist 

Mr. and Mrs. Robert H. Rusher 

Mr. Timothy M. Russell 

Ms. Lauren E. Ryan 

Mr. and Mrs. John Ryan 

Ms. Noreen M. Ryan 

Ms. Harriet E. Ryba 

Mr. and Mrs. Jerrold M. Sadock 

Mrs. Gail L. Sadock 

Safeco Insurance Companies 

Saleeby and Associates 

Mr. Kenneth W. Sandberg 

Ms. Ann M. Sanders 

Mr. James Sarno 

Mr. and Mrs. Robert Scarpelli 

Scatchells Beef Stand Inc. 

Mr. and Mrs. Marvin Schaefer 

Mr. Robert P. Schaible 

Mrs. Anna Mae Scherer 

Ms. Pamela A. Scherzer 

Mr. A. Bruce Schimberg 

Mr. Gary Schinler 

Mr. and Mrs. Robert L. 

Schlossberg 

Mr. and Mrs. William F. Schmidt 

Ms. Nancy L. Schmidt 

Mr. and Mrs. Frank P. Schorsch 

Ms. Suzanne M. Schreck 

Mr. and Mrs. Fred Schuler 

Mr. and Mrs. Stephen Schuler 

Ms. Jenny Schuler 

Mrs. Dorothy A. Schulte 

Ms. Paula M. Schumacker 

Mr. and Mrs. William Schuman 

The Schwab Fund for Charitable 

Giving 

The Alan & Roslyn Schwartz 

Foundation 

Mr. Robert I. Schwartz 

Mr. Larry Schwartz 

Ms. Trudy L. Schwartz 

Mr. and Mrs. Richard D. 

Schwartz 

Alan & Roslyn Schwartz 

Foundation 

Mrs. Dorothy N. Schwartz 

Mr. Scott C. Schweighauser and 

Ms. Elizabeth J. Ellrodt 

Mr. Michael J. Scully 

Sean Patrick’s Salon 

Ms. Eloise V. Searl 

Mr. Scott Seder 

Mr. and Mrs. Stephen P. Seder 

Sedgwick / Detert, Moran & 

Arnold 

Mr. Verne P. Seehausen 

Mr. and Mrs. Robin P. Selati 

Mr. and Mrs. Louis C. Seno 

Ms. Kay Settlif 

Ms. Margaret A. Shanahan 

Ms. Elizabeth A. Shannon 

Mr. and Mrs. Laurence Jay 

Shapiro 

Mr. and Mrs. Jeffrey S. Sharp 

Mrs. Ilene Shaw 

Ms. Patricia M. Sheean 

Ms. Elizabeth Condon Sheffer 

Mr. William R. Shepard 

Mr. and Mrs. Peter Sherman 

Dr. and Mrs. Lowell Sherman 

Ms. Muriel Horn Sherman 

Ms. Wendy C. Sherman 

Mr. Dale S. Sherman 

Ms. Muriel Horn Sherman 

Mr. Harry B. Sherrill 

Mr. and Mrs. Martin Sherrod 

Nancy & Stratford Shields 

Ms. Barbara J. Shifley 

Mr. and Mrs. Bud Sholl 

Mr. and Mrs. Lloyd G. Shore 

Mr. and Mrs. Paul Shukis 

Mr. and Mrs. David Shute 

Ms. Roberta R. Siegel 

Siff Charitable Foundation 

Mr. and Mrs. Jerry G. Silbert 

Mr. and Mrs. Michael Silver 


23

Mrs. Gloria Silverman 

Mr. Charles S. Simon 

Mr. and Mrs. Brian D. Sims 

Mr. and Mrs. Clive Sirkin 

Ms. Kathleen Skapek 

Mr. and Mrs. Gus P. Skizas 

Ms. Carolyn D. Skok 

Ms. Bernadette Skruck 

Ms. Anne K. Smart 

Ms. Susan K. Smith 

Mr. Stephen L. Smith 

Mr. James R. Sneider 

Snelten, Inc. 

Ms. Kathryn M. Soja 

Ms. Lizz Sokolowski 

Mr. and Mrs. Leonard H. 

Solomon 

Mr. Edward D. Somberg 

Mr. and Mrs. Ronald T. Sorrow 

Mrs. Cassie Spencer 

Mr. John L. Spengler 

Mr. and Mrs. Kenneth S. 

Spielman 

Mr. and Mrs. Robert E. Spitler 

Mr. Robert Spitz 

Mr. Gregory E. Spitzer 

Mrs. Nancy M. Spohnholtz 

Ms. Nancy Stankus 

Ms. Corinne Myers Stransky 

Mr. and Mrs. Jerry F. Staroba 

Ms. Laura Staskiewicz 

Mr. and Mrs. Richard J. Stefanski 

Dr. and Mrs. John P. Steichen 

Ms. Barbara Steinhauser 

Mr. and Mrs. Taylor Stern 

Mr. and Mrs. Bernard D. Sterner 

Professors Carolyn and 

Jack Stieber 

Mr. and Mrs. Kevin L. Stoeckel 

Ms. Margaret Stokes 

Mr. and Mrs. William G. Stone 

Ms. Susan Stone 

Mrs. Rhonda L. Stone 

Ms. Mary Strahota 

Mrs. Edward Stransky 

Ms. Sarah Stratton 

Mr. Henry A. Straub 

Ms. Marilyn K. Straus 

Ms. Lynn Straus 

Dr. John H. Strauss 

Mr. and Mrs. Douglas A. Strubel 

Mr. and Mrs. Alexander Stuart 

Mr. Edward A. Suarez, Jr. 

M/M Timothy Sullivan 

Ms. Theresa B. Sullivan 

Ms. Georgean Summers 

Mr. Craig B. Sutter 

Ms. Christine N. Sutton 

Suzanne’s Hallmark Shop 

Mr. and Mrs. John E. Swearingen 

Ms. Janie Swenson and 

Mr. William F. Lewis 

Ms. Janie M. Swenson 

Ms. Olga Swiontek 

Ms. Carol W. Sykes 

Mr. and Mrs. James Taich 

Tap Pharmaceutical Products, Inc. 

Mr. Frank Teacher 

Mr. and Mrs. Earl Temkin 

Ms. Terry J. Thiese 

Mr. and Mrs. Robert Thomas 

Mr. and Mrs. Michael Thomas 

Mr. Joseph M. Thomas 

Mr. and Mrs. Roger J. Thomson 

Mrs. Constance R. Thomson 

Thrivent Financial for Lutherans 

Ms. Jennifer M. Tiernan 

Ms. Christine M. Tierney 

TMNA Wilwin Corporation 

Mr. and Mrs. Stephen G. 

Tomlinson 

Mr. and Mrs. Leon Tonelson 

Mr. and Mrs. John Totten 

Mr. and Mrs. William H. Towle 

Ms. Anita E. Trainor 

Ms. Florence Tucek 

Ms. Karen L. Turano 

Mrs. Ruth E. Ultmann 

Unisource Marketing Group 

United Way/Crusade of Mercy 

Mrs. Eileen C. Van Haren 

Mr. and Mrs. Paul 

Van Witzenburg 

Mr. and Mrs. David Vander 

Zanden 

Ms. Louisa Vassileva and 

Mr. Sean Carney 

Mr. James Vetos 

Mr. Edwin H. Vicich, Jr. 

Mr. John Vinci 

Ms. Faith A. Vitale 

Drs. Tamara and Everett Vokes 

Ms. Joyce M. Volpe 

Ms. Elsa M. Volpe 

Mr. Edward Vonesh 

Mr. James F. Vonesh 

Walsh Landscape 

Construction, Inc. 

The Walsh Family 

Mrs. Patricia S. Walsh 

Mrs. Margaret T. Walsh 

Mr. and Mrs. Leonard Ward 

Mr. Philip L. Watterson 

Mr. Everett P. Weaver 

Mr. and Mrs. Michael Weible 

Ms. Kristen A. Weiler 

Ralph Weiner & Associates LLC 

(Employees) 

Samuel Weinstein Family 

Foundation 

Weld-Rite Service, Inc. 

Mr. and Mrs. Robert Werner 

Mr. and Mrs. Donald Werner 

Donald M. & Barbara Werner 

Family Fdn. 

Mr. and Mrs. Arthur F. Wernli 

Wessel Family Foundation 

Mr. and Mrs. Jeffrey A. Wheatley 

Ms. Judy Wheatley 

Mr. and Mrs. William White 

Ms. Siobhan White 

Ms. Lisa Fredian White 

Ms. Janice M. White 

Ms. Lisa Bowers White 

Mr. Scott E. Whitsitt 

Ms. Maralee Sabath Wicks 

Ms. Christine G. Wieland 

Ms. Kristen Wilcer 

Mr. James A. Williams 

Wine Spirit Distributors of Illinois 

Charitable Foundation 

Wippman, Gozum & Goldberg, 

Ltd. 

Mr. and Mrs. Paul Wisowaty 

Mr. and Mrs. Arnold R. Wolff 

Mr. and Mrs. Lee Wolfson 

Ms. Carmen G. Woodring 

Mr. Chester Wright 

Mr. and Mrs. John Wyle 

Ms. Trilbe Wynne 

Mr. and Mrs. David Yeager 

Mr. and Mrs. Mark A. Yeager 

Mr. and Mrs. Charles G. Yorke 

Mr. Jack D. Young, Jr. 

Mr. and Mrs. Thomas M. Young 

Ms. Laura Yunevich 

Mrs. Suella Zajicek 

Mrs. Sally Vander Zanden 

Ms. Ann E. Ziegler 

Mr. and Mrs. Jeffrey A. Zimmer 

Mr. and Mrs. William 

Zimmerman 

Mr. and Mrs. Jerrold Zisook 

Mr. and Mrs. Ron Zitko 

Ms. Marjorie Zolla 

Ms. Shelley E. Zuraw 

Mr. and Mrs. Leon Zygmun 

*Deceased 

1. Left to right are Women’s Board 2004 

Grand Auction Chairs Joanne Schell 

and Lena Helms, Women’s Board 

President Liz Adams and UCCRF 

Director Mary Ellen Connellan. 

2. Associate Board President Rita Brezina 

and her husband Eric. 

3. Past Auxiliary Board President Liz 

Brandt is flanked by members Annette 

Hickman (left) and Nancy Napalo 

(right). 

4. Auxiliary Board President 

Margo Clavetti Frost with 

Peter Donohue (left) and Bob 

Hickman (right), husband 

of Associate Board member 

Annette Hickman. 

5. Associate Board member 

Taaron Silverstein and her 

father Mark.

Boards and Auxiliaries 

Throughout this annual report, we have discussed the value of collaboration in cancer research. No alliance is more 

important than the partnership between the Cancer Research Center and its volunteers and donors. The University 

of Chicago Cancer Research Foundation (UCCRF) and other supporting boards and auxiliaries form an essential 

community of supporters. This community provides the seed funding that enables our members to pursue their most 

innovative ideas and secure grants from governmental and non-profit organizations. These allies also provide important 

links connecting us with the community and creating an ongoing dialogue. We depend on this interaction and treasure 

the insightful guidance provided by these cherished allies. 

The next several pages introduce you to these committees and their members and review some of the many ways they have 

supported cancer research in FY 2004-2005. 

The Board 

of Trustees 

The Women’s 

Board 

Sustaining Members 

Ruth Ann Gillis McGuinnis, 

President 

Liz Adams 

John Atchison 

James N. Bay, Jr. 

Margaret Benjamin 

Rita Brezina 

Merle Cohen 

Richard W. Cusack 

John W. Derse, Jr. 

Richard L. Duchossois 

Thomas J. Duckworth 

Ronald L. Duitsman 

Nancy Florsheim 

Wende L. Fox 

Stanford J. Goldblatt 

Charles P. Hammersmith, Jr. 

Gwen Klein 

John A Kuhlman, Jr. 

Nancy Napalo 

Lori Ovitz 

Bruce Ovitz 

Gloria Samuelson 

Barton G. Tretheway 

Honorary Trustees 

Seymour A. Cohen 

John D. Gray 

William H. Hartz, Jr. 

Leonard H. Lavin 

J. Clifford Moos 

Mrs. William Adams IV, President 

Mrs. Alexander Anagnost 

Mrs. Helena Appleton 

Mrs. John R. Atchison 

Allison Bacon 

Mrs. James N. Bay 

Margaret Benjamin 

Mrs. Darcy Robert Bonner 

Janna Bounds 

Mrs. James Brady 

Mrs. Harris C. Brumfield 

Mrs. Bernard Burnstine 

Mrs. Michael Joesph Busch 

Mrs. Benjamin D. Chereskin 

Mrs. Gregory Chun 

Ms. Linda Burns Coleman 

Mrs. Robert Conrad 

Mrs. Fred Cook 

Mrs. Thomas L. Cox 

Mrs. Michael Crane 

Mrs. J. Michael Crouch 

Mrs. Richard W. Cusack 

Mrs. Andrew Da Miano 

Mrs. Thomas C. D’Aprile 

Ms. Rebecca Davidson 

Mrs. John Derse 

Mrs. David W. Devonshire 

Mrs. W. Brinkley Dickerson, Jr. 

Ms. Suzette Flood 

Ms. Susan Florence-Smith 

Mrs. Fahey Flynn 

Mrs. David W. Fox, Jr. 

Mrs. Edward Gillette 

Mrs. Thomas T. Hall 

Mrs. Charles Harrold III 

Mrs. Steven S. Helms 

Lesli K. Henderson 

Mrs. William J. Hokin 

Mrs. Steven Edward Johnson 

Mrs. R. Stuart Johnstone 

Mrs. Thomas Eric Kilcollin 

Mrs. Donald A. King, Jr. 

Mrs. Bernard J. Kompare 

Ms. Josephine Krug-Schulte 

Kristine Kurschner 

Karen L. Manzari 

Ms. Amy Mazzolin 

Mrs. Andrew McGaan 

Robin Josephs McGarvey 

Astrid A. McKinnon 

Mrs. Edward J. Miller 

Mrs. David Nuelle 

Mrs. Stuart Oran 

Ms. M. Bliss Packer 

Mrs. Kirby Pearson 

Mrs. Heber Pierce 

Mrs. Gordon Lee Pollock 

Mrs. Frederick Roe 

Mrs. Frank C. Schell III 

Mrs. James H. Schink 

Mrs. Richard Scully 

Barbara C. Sessions 

Mrs. Barton Glenn Tretheway 

Ms. Nancy Voss 

Mrs. Keith Ward 

Mrs. William Wardrop 

Laura Werner 

Ms. Alice Williams-Verhoeven 

Mrs. Gail Kirk Bennett 

Dr. Geraldine Balut Coleman 

Mrs. Robert A. Conger 

Mrs. Jeffrey Diermeier 

Mrs. Gustav Horschke 

Mrs. Donald Horwitz 

Mrs. Robert Kimball 

Mrs. Robert Kramer 

Mrs. Donald Levinson 

Mrs. Edward Liphardt 

Mrs. Michael McGuinnis 

Mrs. Robert Mignin 

Mrs. R. Clifford Potter 

Mrs. Sandra Reese-Stepke 

Samantha Richardson 

Mrs. Harry J. Smedley, Jr. 

Mrs. John C. Stone 

Mrs. Leon E. Zygmun 

Honorary Members 

Mrs. Walter E. Auch 

Mrs. Wendy Becker-Payton 

Mrs. Robert R. Bell 

Mrs. Sharon Brix 

Mrs. Seymour A. Cohen 

Mrs. Alix Engel 

Mrs. Leonard S. Florsheim, Jr. 

Mrs. Maurice Goldblatt 

Mrs. Margaret Laun-Knauf 

Mrs. Arthur MacQuilkin 

Ms. Cindy Reusché 

Mrs. Charles W. Tallent 

Mrs. Charles Walgreen III 

The Women’s Board is a vital contributor to the pursuit 

of the Cancer Research Center’s mission. This year the 

members exceeded their record successes of past years 

and provided the Center with a remarkable donation 

of $635,000. This funding is being used for a variety of 

purposes, which are discussed on the following page. 


25

The Ben May Institute 

for Cancer Research 

Since 1951, the Ben May Institute has advanced cancer 

research by addressing fundamental issues in the biological 

sciences. The Women’s Board’s impressive history of 

funding faculty recruitment and research in the Ben May 

Institute has been critical to its success. The Board supported 

the Institute’s recruitment of a scholar to model and make 

predictions about the multitudes of complex interactions 

and events that occur in a cell. People in business and 

investors use similar models to anticipate changes in the 

marketplace of the stock market. Having the ability to 

model events in biology (to model how a cancer cell works, 

for instance) is the wave of the future, and the Ben May 

Institute intends to be at the forefront. 

Committee on Cancer Biology 

The Women’s Board has long been a friend of the 

Committee on Cancer Biology (CCB), which is one of the 

premier cancer research degree-granting programs in the 

nation. Dr. Geoffrey Greene chairs the committee. His 

predecessor was Dr. Michelle M. Le Beau, the Director 

of the University of Chicago Cancer Research Center. 

Private funding from the Women’s Board ensures that 

the Committee is able to attract and educate the most 

promising students in the world. This year, the Women’s 

Board is helping in the recruitment of young scholars who 

will bring fresh perspective and enthusiasm to the pursuit 

of the Center’s mission. 

Human Tissue Procurement Facility 

The Human Tissue Procurement (HTP) facility collects, 

processes, and stores research-quality clinical material and 

associated clinical information. These specimens are vital to 

basic science, translational and clinical research projects. In 

addition, the HTP also banks tissue for large institutional 

initiatives. The facility requires highly trained staff to 

ensure the viability of the tissue and provide investigators 

with all the clinical and scientific information they need. 

The Women’s Board has helped the core meet these critical 

staffing needs. 

cGMP Facility 

The Women’s Board has been instrumental in the creation 

and development of The University of Chicago Cellular 

and Tissue Based Processing cGMP (current Good 

Manufacturing Practices) Facility. The Board has been a 

supporter since 1997 when the facility was first envisioned. 

This resource provides investigators with a state-of-the-art 

facility in which to prepare cell therapy products for phase I 

and II clinical trials. The facility’s design meets clean room 

and cGMP construction standards of a very high level. 

Drug Discovery, Drug Development 

and Advanced Instrumentation 

The Women’s Board has played an ongoing role in 

the drug discovery process, which develops effective 

therapies that take advantage of new knowledge of the 

minute world of individual cells, genes, chromosomes 

and proteins. Research at this level requires advanced 

instrumentation and sophisticated libraries of chemical 

compounds. The Women’s Board has supported the 

purchase of equipment, which analyzes cancer cells and 

provides detailed information about how these cells 

respond to specific compounds. Such instruments are 

essential for successful and full service drug discovery. 

The Women’s Board has also helped the Cancer Research 

Center purchase libraries of the compounds and small 

molecules. Researchers are using new technology to 

screen the compounds in these libraries to determine 

which ones block the activity of cancer-related proteins. 

Bioinformatics 

Biomedical Informatics is the intersection of computer 

and information sciences with biology and medicine. The 

leadership of the Cancer Research Center has launched an 

ambitious effort to systematically improve its capabilities 

in biomedical informatics, which is enhancing research 

across a broad spectrum of activities. The Cancer Research 

and the Division of Biological Sciences Center recently 

opened a biomedical informatics core facility which 

serves the informatics needs of the faculty. The almost 

overwhelming demand for these services demonstrates 

the value of this facility to researchers. Funding from the 

Women’s Board has helped fuel this successful program. 

Clinical Informatics 

The UCCRC is a national leader in cancer clinical trials. 

These trials are a fundamental part of our fight against 

cancer. The conduct of a clinical trial is subject to constant 

and rigorous clinical, regulatory, and administrative 

oversight. This oversight requires the principal investigator 

to collaborate with many groups here and at multiple 

institutions throughout each stage of the clinical trial 

process. Ensuring the integrity of the research, complying 

with government and sponsor requirements, and most 

importantly, protecting the privacy and safety of our 

patients involves many people managing much critical 

and sensitive data. Funding from the Women Board has 

played a significant role in the Cancer Research Center’s 

successful efforts to improve the quality and efficiency of 

clinical trial management and provide researchers with 

improved, secure access to clinical trials information.

The Auxiliary Board 

Margo Calvetti Frost, 

President 

Celeste Alcock 

Cindy Alston 

Tracy Bismonte 

Susan Bondurant 

Jackie Bossu 

Elizabeth Brandt 

Maggie Flanagan 

Laurie Foster 

Jan Gaines 

Nancy Gupta 

June Ghezzi 

Annette Hickman 

Terri Kingdom 

Darlene Landsittel 

Debbie Madlener 

JoAnn McKibben 

Andrea Montross 

Nancy Napalo 

Karyn O’Connor 

Jan Peterson 

Cathy Pratt 

Linda Russell 

Tam Rustin 

Laurie Shiel 

Tierney Sharif 

Ginger Stambaugh 

Liz Williams 

Christine Youngberg 

Sustaining Members 

Leigh Beith 

Shirley Bennett 

Barbara Bridges 

Anne Collins 

Elizabeth Crawford 

Ann Dougherty 

Ethel Fox 

Susan Fraley 

Jane Hemmings 

Jan Hetherington 

Margaret Jacoby 

Becky Kolleng 

Joan Lancaster 

Betty Ann Manganaro 

Mary Marnell 

Linda McCann 

Jan McKnight 

Mary O’Connell 

Helen Panje 

Mary Helen Ray 

Laura Thomson 

Patti Tyska 

Mary Clare White 

Honorary Members 

Cheri Allen 

Barbara Devlin 

Barbara Grant 

Carol Lynnes 

Patsy McCurdy 

Barbara Schmolze 

Sharon Ubben 

Founded in 1951 by Stephanie Howel, the Auxiliary Board raised $3,000 in its first year. The Board 

was incorporated in 1959 as an official auxiliary of the UCCRF. 

Researcher Support 

In the 2004-2005 Fiscal Year, the Auxiliary Board provided $90,000 to support three cancer researchers: Amy 

Peterson, MD; Karen M. Frank, MD, PhD; and Miriam B. Rodin, MD, PhD. Dr. Peterson develops new forms 

of immunotherapy, Dr. Frank investigates both the immune system and the mechanisms of cancer development, 

and Dr. Rodin studies the effects of cancer treatments on the memory, attention and thinking faculties of cancer 

survivors. 

The Associate Board 

Rita Brezina, President 

Amy Will Brumfield 

Tearle Calinog 

Meghan DeRoma 

Sadie Everett 

Jim Foster 

Amy Herron 

Kristen Karczewski 

Amanda Pierce 

Dan Ryan 

Elizabeth Ryan 

Hayes Ryan 

Lauren Ryan 

Michael Ryan 

Taaron Silverstein 

Rob Soraparu 

Justin Ullman 

Nick Vogelzang 

Although it is the UCCRF’s newest Board, the Associate Board has already 

made significant contributions to advance cancer research and has helped the 

University of Chicago maintain its reputation as a pioneer in the study and 

treatment of malignant mesothelioma. In the 2004-2005 Fiscal Year, the 

Board made a generous contribution of $140,000. 

Mesothelioma Research 

The Board supported mesothelioma research conducted by Hedy L. Kindler, MD, and 

Ravi Salgia, MD, PhD. Malignant mesothelioma is a cancer affecting the lining of the 

chest or abdomen. 

Immunotherapy Research 

The Board provided funds for immunotherapy research. Thomas F. Gajewski, MD, 

PhD, is the leader of the UCCRC Immunology and Cancer Program, which studies 

the body’s immune system and explores ways to enhance its ability to attack cancer. 

The Junior Cancer League 

Mrs. Kenneth Rabin, President 

The League provided $21,000 to support Dr. Melvin L. Griem’s research in radiation oncology. 


27

Income 

2004-2005 Financial Report 

UCCRF Beginning Balance July 1, 2004 $377,354 

UCCRF Contributions 

Unrestricted 89,559 

Restricted Funds 579,546 

669,105 

Auxiliaries’ Income 

Women’s Board 954,134 

Auxiliary Board 90,000 

Associates Board 145,764 

Junior Cancer League 21,000 

1,210,898 

Endowment Income 

UCCRF Board of Trustees 4,287 

Simon M. Shubitz 15,721 

20,008 

Operating Expenses and Allocations $1,887,165 

Ending Balance June 30, 2005 $390,200 

Total Income $1,900,011 

Operating Expenses and Allocations 

Operating 

Personnel 199,235 

Services 216,185 

Supplies 5,770 

421,190 

Allocations 

Research & Faculty Support 579,975 

Women’s Board 635,000 

Auxiliary Board 90,000 

Associates Board 140,000 

Junior Cancer League 21,000 

1,465,975 

UCCRC Financials 2004-05 

Funding Agency 

National Cancer Institute 30,055,120 

Other National Institute of Health 36,884,537 

American Cancer Society 1,333,528 

National Science Foundation 504,625 

Other Peer Reviewed 4,336,732 

Industry Non Peer Reviewed 12,569,064 

Other Non Peer Reviewed 18,974,412 

Gifts/Endowments 11,086,901 

115,744,919

Help Us Continue to Make a Difference 

To learn more about cancer research at the University of Chicago and how 

you can help our researchers pursue promising avenues of investigation that 

would otherwise remain unexplored, please contact Mary Ellen Connellan, 

Executive Director, University of Chicago Cancer Research Foundation, at 

(773) 834-7490 or mconnell@medicine.bsd.uchicago.edu 

A donation to the University of Chicago Cancer Research Foundation is an 

investment in one of the nation’s leading facilities for scientific inquiry and 

will help people here at home and around the world. 

Donations by check may be made to: 

The University of Chicago Cancer Research Foundation 

5841 South Maryland Avenue, MC1140 

Chicago, IL 60637 

All gifts are tax deductible as provided by law. 


Cancer Research Center 

Michelle M. Le Beau, PhD 

Director, the University of Chicago Cancer Research Center 

Professor of Medicine and Human Genetics 

Marcy A. List, PhD 

Director for Administration 

Scientific Director, Cancer Clinical Trials Office 

Marsha R. Rosner, PhD 

Deputy Director 

Charles B. Huggins Professor and 

Director, Ben May Institute for Cancer Research 

Professor of Neurobiology, Pharmacology and Physiology 

Everett E. Vokes, MD 

Deputy Director 

John E. Ultmann Professor of Medicine and 

Director, Section of Hematology/Oncology 

Professor of Radiation and Cellular Oncology 

Geoffrey L. Greene, PhD 

Associate Director for Basic Sciences, and Education 

Virginia and D. K. Ludwig Professor and 

Associate Director, Ben May Institute for Cancer Research 

Professor of Biochemistry and Molecular Biology 

Chair, Committee on Cancer Biology 

Mark J. Ratain, MD 

Associate Director for Clinical Sciences 

Leon O. Jacobson Professor of Medicine 

Chair, Committee on Clinical Pharmacology and Pharmacogenomics 

Paul J. Butera, PhD 

Director for Communications 


Director, the University of Chicago Cancer Research Foundation 

Jay Lewis 

Director for Informatics and Technology 

Maria Reyes 

Director for Finance 

Consuelo Skosey, RN, CCRP 

Director for Clinical Research Operations 

Technical Director, Cancer Clinical Trials Office 

convergence 

Editor: 

Paul J. Butera, PhD 

Design and Printing: 

Pixel Print Graphics 

©2005 The University of Chicago Cancer Research Center. 

All rights reserved.

5841 South Maryland Avenue, MC1140, Chicago, IL 60637 

www.uccrc.org

convergence - The University of Chicago Medicine Comprehensive ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?